1.b.2. Dr. Emanuel Revici, 1896-1998, non-toxic lipid chemo therapy, including Omega-3-ALA and Omega-6-LA

The legend versus the lowlifes

We are fully entitled to consider my approach as a highly beneficial treatment. When correctly applied it can in many cases even bring advanced malignancies under control.

-Dr. Emanuel Revici

–

Health is based on two dynamic forces in all living organisms”Catabolism (breaking down, acidic) and Anabolism (building up, alkeline).

-Dr. Emanuel Revici

Did the Burrs influence Dr Emanuel Revici (Bucharest, September 6, 1896- New York, January 9, 1998), or did he influence them?

They were first to publish, but he had researched ^{Linoleic-Acid} before they did.

Emanuel Revici’s method for treating cancer

Dr. Emanuel Revici pioneered nontoxic lipid treatments for cancer in the mid-1920s . He has treated cancer for70 years and cured thousands and thousands and thousands of patients of cancer ¹

.

He was the first research clinician to treat cancer with Omega-3-ALA ². Combining Newtonian physics and quantum mechanics, he redefined lipids, accurately describing their molecular activity, organization, and properties ³ .He used Omega-3-ALA combined with sulfur to cure cancer ⁴.

Sulfur ⁵occurs in foods as part of protein: milk, legumes, nuts.

Dr Revici said that this combination killed tumors in rats and in people.

The tumor is dead after a month, but takes a 3 or 4 months to disappear. Once it is dead, it does not cause any pain anymore.

In this lecture⁶ from 1986, Dr Revici says that free fatty acids only occur in the lesions. A lesion is any damage or abnormal change in the tissue of an organism, usually caused by disease or trauma. Lesion is derived from the Latin laesio “injury”. ⁷The ingested or injected fatty acids with sulfur survive the stomache, are transported through the blood and bind to the free fatty acids in the tumor and kill the cancer. He calls that the secret of his therapy.⁸ It is an atomic absorption.

His discovery has 3 parts.

1. the lipid:

2. he combines the lipid with the substance that he wants to transport to the tumor, like berylium, sulfur, or selenium. (all catabolic, acidic)

3. The lipid brings the substance to the cancer, because it brings it to the free lipid. So you have a targeted approach this way. Sulfur works best.

Sulfur in the lipid works. Just the sulfur does not work, for example sulfur in a water solution does not work.

The lipid is taken by the lipids in the red blood cells and goes where there is a free lipid, and goes there in 15 minutes whether you inject it or ingest it.Within 15 minutes the pain stops, It is even a way for detecting tumors⁹.

Lipids are mostly in the membrane of the cell. They are in the membrane of the chromosome. Where there is a membrane, there is a lipid. We are a lipidic world, totally dependant on lipids.

The lipid we ingest finds the lesion, because that’s the only place where there are free lipids. So the ingested lipid binds to free lipids, thus targetting the cancer.

There is no relation between arthritis and cancer.

Dr Revici says that elements and vitamins are anabolic (constructive, alkaline) or catabolic (destructive, acidic) in nature. The schedule below shows which he categorized as anabolic and which as catabolic

Revici’s Periodic Chart of Anabolic and Catabolic Elements

The Catabolic Vitamins according to Revici are:

A ( as in Bèta Carotene)¹⁰, D (as in sunlight)¹¹, B6 and B12 and E^{12 13} .¹⁴ These he gives to fight cancer.

The other Vitamins are anabolic.

Revici also emphasized the psychological aspect, that they had hope again and that helped with the healing as well. Heisihting for lie biologically and spiritually He said chemotherapy and radiation do not work. His treatment with Omega-3-ALAand sulfur works against AIDS as well He saw cancer as a parasite,The tumor is painful when it reaches the connective tissue Sulfur lipids work against cancer. ¹⁵

Dr Revici advises to take the sulfur-lipid combination once a week as a preventative measure against cancer.

The following is an excerpt rfrom one of Revici’s admirers:

Experiments with dilute phosphoric acid yielded approximately converse results.

Knowing that such small amounts of dilute base or acid would not change bodily pH, he then placed platinum electrodes into painful loci of patients with superficial tumors, as well as into non-painful regions of the tumor mass and into normal tissue.

These experiments led to a remarkable conclusion: The pH of painful local lesions was not only different from the rest of the body, but could be rapidly and specifically altered by the ingestion of small amounts of acid or base.

As a result of these initial studies, Revici proposed that a critical distinction be made between pathological pain and what he termed “physiological pain,” a distinction supported by many subsequent years of research.¹⁶

Wishing to relieve pain in his cancer patients, he decided to develop lipidic means of altering pH, realizing that interventions based on ions, amino acids, or proteins would prove too shortlived to provide meaningful benefit.

Before he could carry out this work, however, he determined that it was necessary to define lipids as more than greasy, water-insoluble substances extractable in ether (a definition still found in many present-day biochemistry books).

Decades earlier than anyone else in the field, he redefined these important substances at a molecular level, describing accurately the relative importance of the polar and non-polar regions of these molecules.

This definition guided his utilization of lipids for therapeutic purposes by providing a precise structural guide to the analysis of compounds he would go on to create.¹⁷

While seeking to develop better means of analyzing the effects of lipids on the organism, and being intrigued by his observations that the mineral constituents of the nuclei and cytoplasm resembled the earth’s crust rather than sea water,

Revici also initiated a systematic study of the effects of different elements on bodily function. ¹⁸

This research led him to categorize elements as to whether they primarily were inductive of anabolic (building up) or catabolic (breaking down) metabolism, terms which, to some extent, became interchangeable

in his thought with categorization according to whether an element contributed to an alkaline (building up) or acidic (breaking down) state.

Remarkably, he found that within a vertical series of the Periodic Table of the Elements, elements acted similarly; and he deduced that their valency shell in part determined their bioactivity.

Based upon his analysis of elements in different levels of organismal organization (cell, tissue organ, system), and the effects of specific elements on cellular pathology, he suggested that the concentration of an element in different organizational levels was both precisely regulated and a critical determinant of normal and pathological states.¹⁹

A further component of Revici’s development stemmed from his observations on the molecular structure of carcinogens and other bioactive molecules.

In contrast to the prevailing wisdom (expressed most forcefully by Linus Pauling), he observed that many bioactive molecules exhibited a charge structure in which adjacent carbon atoms would be predicted to carry identical charges.

As with so. much of his work, examination of molecular structures makes one wonder why his peers resisted this discovery: Perusal of the Merck Index reveals example after example of bioactive molecules with such an energetic configuration.²⁰

The concepts Revici evolved from study of these “twin formations” (as he termed them), or energetic centers, also played a crucial role in his design of medicaments.²¹

Time after time, his investigation of lipid function and chemistry opened the way to findings that predate ideas now widely accepted.

For instance: 20 or more years before Bengt Samuelsson²² described leukotrienes, receiving a Nobel Prize for his work²³ Revici described them in essence, recognizing their crucial role in inflammation.²⁴

Typically for him, though, he also saw these compounds as a small part of a much larger picture.

Instead of choosing the traditional scientific path of focusing the next 10 years of his research on this one topic, he went on to describe presciently the capital role of bioactive lipids in the early stages of cellular and systemic host defense processes, deducing that intervention by lipids at this level of the body’s defenses might drastically alter outcome, and even the extent of mobilization, occurring at other levels²⁵.

At this stage in his development, Revici incorporated another important foundation principle: That frequently the damage done to any organism by disease is caused not by the pathogenic focus but by the body’s defense mechanisms as well.

Although he may not have been the first to codify this key principle, he again seems to have been decades ahead of others in applying this understanding of pathology in his treatment²⁶.

Because he believed that these defense mechanisms, activated into disequilibrium, may do more harm than the pathogenic focus itself might, he therefore devoted himself to devise medicaments that would restore normal bodily function.

Based upon his earlier studies, he chose to utilize the properties of elements to alter different levels of function, and the ability of lipids to cause longer-lasting alterations, to create a large series of therapeutic compounds in which elements were conjugated into lipids²⁷ : He thereby anticipated, again by decades, interest in lipids as carriers of pharmaceutically useful compounds²⁸.

As already noted, his research on “twin formations” also heavily influenced his thought on the structure of useful therapeutic agents.

Taken altogether, the different paths of research he explored during his life facilitated the development, with foresight and intention, of a great number of therapeutic compounds designed to have particular effects.-on the function of normal and diseased tissues said, then, in summary, and without exaggeration, that Revici developed a theory of rational drug design decades before the concept entered the imagination of the larger scientific community. And this theory helped him to discover, among other therapeutic agents (again, many years before anyone else did), such compounds as organo-selenium drugs for treatment of cancer, AIDS, and other terminal or chronic degenerative diseases.

His nontoxic chemotherapy uses lipids, lipid-based substances, and essential elements to correct an underlying imbalance in the patient’s chemistry.

This was his theory:

1. High tissue/cell cholesterol (TCh), calculated from serum cholesterol results, is a pathologic lipid defense resulting in anaerobic metabolism. High tissue/cell cholesterol(TCh) often corresponds with an elevated LDL cholesterol.
2. Low tissue/cell cholesterol (TCh), calculated from serum cholesterol results, often corresponds to high HDL and/or low LDL cholesterol. Low tissue/cell cholesterol (TCh), indicative of runaway inflammation and lipid peroxidation is seen in, or predicts, autoimmune disease.
3. Pain is either from tissue acidity or tissue alkalinity. The dysaerobic metabolism of pathological fatty acids creates tissue alkalosis.  The anaerobic metabolism of pathological sterols and steroids generates acid tissues. The former responds to fatty alcohols that neutralize fatty acids; the latter to reduced sulfur.
4. Lipid-bound minerals are readily absorbed and delivered by red blood cells to sites where a deficiency contributes to pathology.
5. Low serum potassium is often a result of an extra- to intracellular potassium shift..²⁹

Lipids-organic compounds such as fatty acids and sterols-are important constituents of all living cells. They are a separate, critical system in the body’s defenses against illness, according to research conducted by Dr. Revici early in his career.

Unlike cancer cells, which are only able to transfer sugars into energy, healthy cells are also able to convert fats and proteins into energy³⁰. So eating healthy fats strengthens the healthy cells, but does not feed the cancer cells.

The liver primarily uses fatty acid oxidation for energy. Muscle cells use fatty acids,³¹ glucose, and amino acids ³²as energy sources. Most cells use glucose for ATP synthesis, but there are other fuel molecules equally important for maintaining the body’s equilibrium or homeostasis. ³³

Look here to see which fats are healthy and how you can consume them.³⁴

Selenium³⁵ rich foods are Brazil nuts, cottage cheese, eggs, brown rice, sunflower seeds, oatmeal, mushrooms, spinach, milk and yoghurt, lentils, cashews and banana’s. Like Johanna Budwig put in her famous porridge to treat cancer patients.

Revici’s medical findings derived from a number of different lines of investigation, each simple enough by itself. Interwoven, they make a complex body of knowledge.³⁶The starting point was an observation Revici made in the 1920s, while, lilke the 20th century. he was also still in his 20s.

During the early years of his clinical research, he noted that cancer patients presenting with pain showed a cycling in their levels of discomfort. Some patients felt more pain in the morning. Others suffered more at night Some patients had their pain relieved by eating, Others found their pain so exacerbated by eating that eating became a fearful experience for them.

Revici surmised that any cycling of this nature must be associated with an underlying cycling of the patients’ physiology, and he set out to discover what such underlying fluctuations might be.

Hypothesizing that this cycling might relate to an underlying cycling of the patients’ physiology, Revici looked at various aspects of blood and urine. His investigations showed that healthy persons typically had daily rhythmic fluctuations in such basic physical parameters as urinary pH and levels of free potassium in the blood. In contrast, cancer patients had abnormal fluctuations, showing either patterns of acidic imbalance or alkaline imbalance.³⁷

Further investigation found that patients in acidic imbalance could relieve their pain temporarily by ingesting a small amount of sodium bicarbonate. But patients in alkaline imbalance who ingested sodium bicarbonate suffered worse pain.

Repeating the experiment with dilute phosphoric acid gave roughly converse results.

Realizing that these small amounts of dilute acid or base wouldn’t change bodily pH, Revici next placed platinum electrodes in painful loci of patients with superficial tumors, as well as in non-painful parts of the tumor mass and in normal tissue.

All these experiments led Revici to conclude that the pH of painful local lesions was not only different from the rest of the body, but that ingestion of small amounts of base or acid could specifically and quickly alter these painful lesions.³⁸

As a result of these studies, Revici proposed that a crucial distinction be made between pathological pain and what he termed “physiological pain” (a distinction supported by many subsequent years of research).

To ease pain in his cancer patients, he then turned to developing lipidic means to change pH, recognizing that interventions based on amino acids, ions, or proteins would not last long enough for meaningful relief.

Before proceeding, he felt it necessary to redefine lipids (fatty acids and sterols), which were generally regarded in the early 20th century as greasy, water-insoluble substances extractable in ether, a definition that still appears in many biochemistry books.³⁹

Decades ahead of anyone else in the field, Revici described lipids at a molecular level, correctly noting the importance of their polar, hydrophobic carboxyl head ⁴⁰and non-polar regions. ⁴¹ (the methyl tale and the rest of the molecule is non polar)

As his career progressed, Revici’s definition guided his clinical use of lipids by supplying an accurate structural guide for analysis of therapeutic compounds he wished to create.⁴²

During his European years, Revici also launched into a systematic study of the effects of different elements on bodily function, a research path ending in his categorization of elements as either inducing anabolic or catabolic states of metabolism.

Later, he discovered that within a vertical series of the Periodic Table, elements acted similarly – their valency shell partly determined their bioactivity, and the concentration of an element in different organizational levels of the body was both precisely regulated and a key determinant of normal and pathological states.⁴³

By the time he had emigrated to the US, Revici’s investigations into the molecular structure of carcinogens and other bioactive molecules had revealed that many bioactive molecules exhibited a charge structure in which adjacent carbon atoms would be predicted to carry identical charges.

The concepts Revici evolved from study of these “twin formations” (as he termed them), or energetic centers, also played a crucial role in his design of therapeutic agents.

As with so much of his work, examination of molecular structures makes one wonder why Revici’s American peers resisted this discovery: Flip the pages of the Merck Index, and example after example of bioactive molecules with such an energetic configuration march by.⁴⁴

Repeatedly, Revici’s studies on lipid function pointed the way to findings that predate ideas widely accepted today.

Decades before Bengt Samuelsson reported on leukotrienes, earning a Nobel Prize, Revici essentially described them, indicating their crucial role in inflammation.⁴⁵  

This was what the 1987 study Bengt Samuelsson was part of claimed:

“Arachidonic-Acid is released from membrane phospholipids upon cell stimulation (for example, by immune complexes and calcium ionophores) and converted to leukotrienes by a 5-lipoxygenase that also has leukotriene A4 synthetase activity. Leukotriene A4, an unstable epoxide, is hydrolyzed to leukotriene B4 or conjugated with glutathione to yield leukotriene C4 and its metabolites, leukotriene D4 and leukotriene E4. The leukotrienes participate in host defense reactions and pathophysiological conditions such as immediate hypersensitivity and inflammation. Recent studies also suggest a neuroendocrine role for leukotriene C4 in luteinizing hormone secretion. Lipoxins are formed by the action of 5- and 15-lipoxygenases on arachidonic acid. Lipoxin A causes contraction of guinea pig lung strips and dilation of the microvasculature. Both lipoxin A and B inhibit natural killer cell cytotoxicity. Thus, the multiple interaction of lipoxygenases generates compounds that can regulate specific cellular responses of importance in inflammation and immunity⁴⁶  ”.

It was characteristic of Revici, though, to view these compounds as part of a much larger picture. Instead of choosing to concentrate on this one topic for years, he swiftly moved on to elucidate the role of bioactive lipids in the early stages of cellular and systemic host defense processes. Intervention by lipids at this level of the body’s defenses, he reasoned, might affect outcome and even the extent of mobilization at other levels⁴⁷.

As he developed his theories and applications, Revici incorporated another basic insight: The damage caused by disease frequently isn’t done by the pathogenic focus alone, but by the body’s defense mechanisms as well. He may not have been the first to codify this key insight as a therapeutic principle, but once more, he seems to have preceded the mainstream in incorporating the principle to treat patients⁴⁸.

Because Revici believed that these defense mechanisms might do more harm than the pathogenic focus itself (once activated into disequilibrium), he devoted himself to devising therapeutic agents that could restore normal bodily function. Based on his European research, he utilized the properties of elements to alter different levels of function and the ability of lipids to induce longer-lasting alterations to create a large series of therapeutic compounds in which elements were conjugated into lipids. He thereby anticipated, again by decades, interest in lipids as carriers of pharmaceutically useful compounds.⁴⁹

In sum, the different paths of research Revici followed throughout his career enabled him to pioneer, intentionally and with foresight, a great number of therapeutic compounds designed to produce specific effects on the function of normal and diseased tissues. Without exaggeration, then, one may say that he developed a theory of rational drug design long before the concept entered the imagination of the larger scientific community.⁵⁰

A Nobel Prize was awarded to scientists in 1982 “for their discoveries concerning prostaglandins and related biologically active substances“⁵¹, a discovery the Burrs, had already written their research paper on in 1929, and with which Dr. Revici and Dr. Johanna Budwig had already worked fifty years earlier.

While physicians and scientists have confirmed some of his discoveries in recent decades, many remain unrecognized.

The same transformation that occurred in physics a century ago will occur in medicine this century once Dr. Revici’s work, the physics of lipids, is appreciated and applied.⁵²

Dr. Revici was also the first physician to develop selenium compounds to give cancer patients and he was among the first research clinicians to treat cancer with naturally derived Omega-3-ALA.^{53 54}

Dr. Emanuel Revici has developed an original approach to the treatment of cancer but he was able to heal many other ailments and diseases as wll.

Dr Brenner’s praise of Emanuel Revici’s Method for Curing Cancer

In the earlier mentioned lecture⁵⁵, Revici says he is hopeful that Dr Brenner would be helpful in promoting his research.

Dr Brenner, a retired radiation oncologist, wrote the foreword of The Doctor Who Cures Cancer by William Kelley Eidem. From which the following biographical exerpts are taken. It is a very powerful acknowledgment of Dr. Revici’s method :⁵⁶

Dr. Brenner’s Foreword to Kelley Eidam’s book The Doctor Who Cures Cancer⁵⁷

Dr. Emanuel Revici treats cancer in a manner unlike any other doctor in the United States and probably in the world. He uses his own medicines. Over the years he has developed over 100 different medications in his own laboratory. I don’t know how they work, but I have seen their results.

I am a retired board certified radiation oncologist. My practice specialized in the treatment of cancer with radiation. I have fought at the front lines in the war against cancer all of my professional life. During my long tenure of battling cancer for my patients, I gradually became rather frustrated and unhappy with the little progress that has been made in the treatment of this disease

After more than forty-years of seeing almost no breakthroughs on the medical front, it became painful seeing my patients every day, knowing that most of them had very little chance for a cure. On numerous occasions I saw patients in tears. Just as often I saw wives crying for their husbands, husbands crying for their wives, and parents crying for their sick children.

My combined Brooklyn and Queens offices handled several hundred appointments a week during the last ten-years of my practice, making it the largest cancer radiation oncology center in the nation. Highly regarded physicians whose offices were in the shadows of Sloan-Kettering, Columbia University College of Physicians and Surgeons and NYU Medical Center sent their patients to our offices. I was a member of the Cancer and Acute Leukemia Group “B”, which is the largest nationally funded cancer research group in the United States. Our office provided this organization with statistical data regarding our patients.

My practice produced a personal income for me well into the seven-figure range annually. For four decades our offices were technologically state-of-the-art. We repeatedly spent millions of dollars in order to procure the latest and best radiation and diagnostic equipment available. Despite that outward success, I am still saddened from having watched so many people of all ages die.

Even with the best possible equipment and a staff of board-certified radiation oncologists, we could only do so much. Sadly, for the population of patients we saw, the odds were against them. Many came to us hoping to be cured. When I examined their records, though, I knew which ones were being treated for a possible cure, and which ones were being treated for palliation (relief of pain).

Since 1950, the medical profession has made only minor advances in the therapeutic arena against cancer. The only significant improvement that I saw was in our diagnostic abilities. As a result, some cancers, such as cancer of the breast, colon, uterus and prostate have cure rates of 90% or better if caught in Stage 1. I must state, however, that these four highly curable cancers become incurable if not caught in their early stages – Stages I or Il. Although the overall numbers say you have a fifty-fifty chance of beating cancer, the individual numbers say you either have a 90% chance or very little chance, depending on what stage the cancer is in and its type. Unfortunately, for a few cancers, such as pancreatic cancer, the patient is lucky to live much more than six months, regardless of the treatment. Even with the all-out effort to catch cancer earlier than ever before, the overall five-year cure rate has inched up a paltry 0.7% in the last 40-years.

I first became interested in Emanuel Revici M.D., not from the medical literature, but from hard evidence – that is, X-rays taken at my office of one of my patients. I knew his prior condition, because this was a patient we had seen a year earlier. His cancer of the lung had metastasized to his bones.

There was no mistaking the improvement in the patient When I saw that his new films showed no evidence of the cancer either in his bones or lungs, I had to find out what caused the remission.

The patient told me he had been undergoing treatment by a Dr. Revici in Manhattan. At the time, I was unfamiliar with the gentleman. Still I arranged to meet with him at his office. When I first met Dr. Revici~ he was already 90-years-old. He showed me enough before and after X-rays and CT scans at our first meeting for me to schedule a second one.

A few days later he introduced me to three patients who had previously been stricken with incurable cancer. Two of them had been afflicted with pancreatic cancer and the other was previously diagnosed with a malignant brain tumor. Dr. Revici showed me their CT scans both before and after his treatment. The before’ pictures showed a suspicious mass for each patient. He also showed me the written biopsy reports from the various hospitals which had confirmed that the abnormal masses were cancerous. The ‘after’ scans showed no evidence of any abnormality. From all outward appearances, the three patients looked to be healthy. Dr. Revici also showed me copies of the reports from the patients private physicians who confirmed that the patients were now free of cancer.

I knew from my own training and experience that modem medicine couldn’t have saved those three people. Each of the three patients had an almost zero percent chance of recovery. That all three would be free of cancer led me to think that Dr. Revici’s medicines were worth further investigation.

Since those early meetings, I have reviewed the records, X-rays, CT scans and biopsy reports of dozens of Dr. Revici’s patients. Often, when Dr. Revici provided me with information on a patient I would attempt to confirm it with the patients previous physicians. I soon found out that every time Dr. Revici had provided me with information regarding a patient It would turn out to be correct.

As a Diplomat of Radiology I have reviewed many cases of incurable cancer that Dr. Revici has cured. I must admit that his results aren’t always 100% but then neither are the results of the approved medical profession 100%.

In my entire career of seeing tens of thousands of patients, I have never seen a single case of spontaneous remission, except for misdiagnosed lung cancer. The cases I reviewed at Dr. Revici’s office were not misdiagnosed. In my opinion, its unlikely that the positive outcomes I reviewed were the results of multiple spontaneous remissions.

I must interject a brief story at this point. When I met Dr. Revici~ I was sixty-two-years-old. My PSA reading, the screening test for prostate cancer, was 6.2. A PSA score of up to 5.0 is normal. Scores from 5.0 to 10.0, need to be watched, as some may indicate the presence of cancer. Above 10.0, there’s a greatly elevated chance of cancer.

I told Dr. Revici about my PSA score, so he gave me one of his medications. After taking the medicine for a year, my PSA reading fell to 1.6. There were no apparent ill effects. After a few years of being off the medicine, my latest PSA score has inched up to 2.5.

After examining the records of a number of his patients, I am now of the opinion that Dr. Revici has something worthy of a thorough clinical trial. I decided to see if I could help Dr. Revici to conduct a large scale test of his method and his medicines.

I made a presentation at the Congressional hearing in March of 1988. At that time I proposed a study to test Dr. Revici’s method for treating cancer, Once it is approved, the study will include 100 cases of cancer that the medical profession recognizes as incurable: pancreatic cancer, colon cancer with liver metastases, unresectable lung cancer and unresectable brain cancer. The patients are to be selected by five board-certified oncologists who will verify that each patient is incurable, and that his or her life expectancy is less than one year.

Sloan-Kettering, NIH, The Mayo Clinic, M.D. Anderson, John Hopkins and many other outstanding research centers accept cancer patients for experimental trials every day.

The patients who volunteer often decide to participate because they believe it might give them a chance they might not have otherwise. I believe its time to conduct an experimental trials of Revici’s medicines. These patients would have nothing to lose by their participation. From what I have seen, there is the chance that they would have something to gain.

Dr. Revici has cured many people who were otherwise considered incurable. It is my professional opinion that his medicines have worked for many of the patients whose records I have examined. Lets find out if more patients and their families can be helped. The fact that he has helped so many people means its time for Mr. and Mrs. America to push for a clinical trial of his method.

-Seymour Brenner, M.D., F.A.C.R.

Many Doctors Praise Dr. Emanuel Revici

He wasn’t the only one to praise Dr Emanuel Revici.Below are a few thoughts about Dr. Revici expressed over the years by medical doctors, scientists, researchers and patients. ⁵⁸

His brilliance as a medical scientist

Professor Joseph Maisin (Nethen, Beligium, 1893- Seville Spain, June 1, 1971), ⁶⁰Director of the Institute of Cancer, University of Louvain,Belgium (former director of the International Union Against Cancer), found Revici’s medications effective in numerous terminal cases refractive to other treatment.⁶¹

Gerhard N. Schrauzer, PhD (Professor of Chemistry, University of California, La Jolla), an authority on selenium, has credited Revici with “having discovered pharmacologically active selenium compounds of very low toxicity,” appraising him as “an innovative medical genius, outstanding chemist, and a highly creative thinker.”⁶²

Mark Noble, PhD (Professor of Oncology, University of Utah), a noted cell biologist, is currently “studying Dr. Revici’s work because there is a significant chance that he has created a coherent chain of scientific discoveries”⁶³

Dr. Emanuel Revici is the Louis Pasteur of our time—brilliant, innovative, compassionate, and always at the vanguard of applied research. A man who has lived long enough to see his ideas benefit tens of thousands—a real treasure!

Gary Null, Ph.D. Author, radio talk-show host.

There was Hippocrates, there was Galen, and then there was Paracelsus. He is among them.

Gerhard Schrauzer, Ph.D. Professor of Chemistry Internationally recognized cancer researcher.

(Actually, comparing Revici to Galen is not such a compliment. He was more like Vesalius I would say)

Emanuel Revici is widely regarded as an authentic genius of modern medicine. To some he ranks on the order of a Pasteur. [He is] sometimes regarded as the Nikola Tesla of medicine.

Robert G. Houston Award-winning science writer and researcher Consultant on alternative cancer therapies for ABC, Metromedia, PBS, and WNBC from Repression and Reform In The Evaluation of Alternative Cancer Therapies, Project Cure, Inc.

My father, who was the science editor of the American Cancer Society for 25 years, and I met with Dr. Revici for the first time on a summer’s day in the mid 1970’s. After two hours of discussion, we left and walked down Park Avenue. I said, “I have to confess I didn’t understand a word that man said.” He said, “I didn’t understand one word either, but I am absolutely convinced—that man is a genius.”

Patrick M. McGrady Jr. Former Moscow bureau chief for Newsweek director of CANHELP, a cancer-patient information and referral service

Genius is seeing what everyone else sees and thinking what no one else thinks. Revici is a genius.

Robert Fishbein, M.D. 34-year survivor of terminal brain cancer under Dr. Revici’s care

Revici is 50 to 100 years ahead of his time in his knowledge of steroids. His work with steroids alone is earth shattering. I’m not fit to tie his shoelaces. In a hundred years people will say, “Isn’t it a shame the way people treated Revici when he was alive?”

Morris Mann, M.D. Researcher and independent inventor.

I saw his book and a thousand lights went on. It’s part of how I think.

Lynn August, M.D. referring to Revici’s textbook.

Dr. Revici’s work is an excellent example of advances in medicine that are far beyond the scope of orthodox medicine.

Robert Atkins, M.D. Atkins Center for Complimentary Medicine Author of Dr. Atkins’ New Diet Revolution

His results with cancer and AIDS You requested that I look into Dr. Revici’s treatment of cancer. This I did, and find it far beyond my wildest expectations…. His results are amazing…

Louis E. Burns, M.D.

Dr. Revici has cured many people who were otherwise considered incurable. It is my professional opinion that his medicines have worked for many of the patients whose records I have examined.

Seymour Brenner, M.D., F.A.C.R. Former head of the largest radiation oncology center in the United States.

I’ve known him for ten years. I don’t know how he does it, but people walk in dead and walk out alive.

John Heller, M.D. Former Medical Director of Sloan-Kettering Memorial Cancer Center

I know of no conventional oncologist who can match his results.

Patrick M. McGrady Jr. from “The Cancer Patient’s Quandary”, The Newsday Magazine,

I tracked down over 200 of Dr. Revici’s cases. I studied this man’s work for 15 years. I refused to write an article about him for ten years until I had absolute proof from my own investigation that [these] patients had cancer…it was his treatment that put them into remisssion, and they were alive and well ten years later.

Gary Null, Ph.D.

Dr. Revici has been working in my laboratory for two years…It is vital that his research be continued without interruption, for the results obtained by Dr. Revici open a multiplicity of new paths to research of all kinds, particularly in the field of cancer.

Roger. Leroux, M.D. Professor of Pathologic Anatomy Faculty of Medicine in Paris Deputy Director of the Institute of Cancer of Villejuif

Dr. Revici’s research in lipids and their therapeutic application in HIV infection and AIDS has proved to be extremely effective—a fact reflected by improvement of “T” lymphocyte counts and clinical conditions as well. His work is definitely promising and opens vast areas of investigation and study in the field.

Carolina Stamu, M.D.

While many European and American Pharmaceutical companies are looking at protease inhibitors and transcriptease, we feel the real good investment lies on the treatment protocols like what you and Dr. Corsello are doing, a model that has positioned James Mobb as the only Southern African Centre getting wheelchaired AIDS patients back to their work places in weeks.

Richard Ngwenya, M.D. Harare, Zimbabwe Referring to protocols developed by the Revici Life Science Center (1997)

When I worked with Revici in the early and mid-eighties, I saw terminal AIDS patients who improved. Some lived almost normal lives.

A.R. Salman, M.D.

There were people who came in who had AIDS who looked like they were at death’s door. You came back a month or two later, and the difference in terms of their improvement was just incredible. He didn’t rescue them all but, my Lord, he pulled a lot of people out.

Robert Wilden, a Revici patient and a nine-year victor over cancer of the jaw

Lastly, there is the list of cancer patients in the U.S., spanning half a century, reportedly in long-term remission under his method of treatment after failing to benefit in any way from accepted modes of therapy.

Now, it is officially recognized that the nutrients he used in his therapy do indeed cure cancer.⁶⁴

Revici’s results with drug and alcohol addiction

The results and what we witnessed [were] so unbelievable that the doctor from Municipal Hospital has now gone back on a daily basis in order to continue with this chance to see the miraculous results that have taken place. Congressman Charles Rangel U.S. Congressional Select Committee on Crime Hearing April 1971. Referring to Revici’s success with drug addiction.

All the patients are drug addicts—heavy long-term users… Normally they should be climbing the walls, vomiting incessantly, clutching their bellies in the agony of withdrawal. Despite the assurances they have received, they seem surprised that they aren’t suffering. “I feel fine, doctor,” they all say, as Dr. Revici questions them. “No problems.”

David A. Loehwing, Barron’s Sept. 11, 1972 Reporting on patients’ experiences with Revici’s detoxification methods for drug addiction.

His alleviation of pain without the use of narcotics I forgot how much pain there is. I was absolutely shocked by the amount of pain that was there at a very good research hospital. They were screaming in the halls. They were lying on the floor tearing up sheets. With Revici, which were really all terminal cases, there was really very little pain.

Lawrence LeShan, Ph.D. Author of Cancer as a Turning Point

Comparing Walter Reed Hospital with Revici’s Trafalgar Hospital. …in cases of patients afflicted with grave surgical conditions…the results obtained in the most hopeless of cases were always the amelioration of pain, and quite often the progressive disappearance of large tumors. Dr. Revici’s research must be continued and fostered, and may change the therapy of tumors completely.

Dr. Chifoliau Honored Member of Hospitals of Paris Member of the French Academy of Surgery …

the thing that impressed me more than anything else is the fact that every patient in this institution is free of, or practically free of, pain without the use of narcotics. In my opinion, if he has nothing else, this ability to relieve intractable pain is a great contribution.

C.A. Calhoun, M.D.

His dedication to his patients I have never seen a more dedicated physician. I have never known before a physician who told every charge nurse in the hospital that if he was needed at any time, by any patient, he should be called and, to my personal knowledge, if he was called at two, three or four in the morning, he was always there within twenty minutes.

Lawrence LeShan, Ph.D.

You could call him at home any day, at any time. We called him three times on Christmas day, including at 6:41 in the morning and 9:14 at night, plus at 6:30 in the evening on Christmas Eve. I kept a tab on all the calls we made. It totaled 437 calls. Pierce and Allan Hamilton,

parents of Andrew Hamilton, patient.

Dr. Revici heard about a patient who was too sick to come and see him. He paid the man a house call, walking up five flights of stairs. Revici was ninety-three.

Marcus Cohen Revici historian

His effect on the future of medicine His lifework is a rich vein of gold waiting to be mined. Dwight L. McKee, M.D. Whether you are a medical or a non-medical person, when you hear the stories of these cases, when you see the x-rays of bones eaten away by cancer and then returning to normal, how can one but believe? I hope we can get more medical people to see the light and put his treatment into practice.

Louis E. Burns, M.D.

It’s not alternative medicine; it’s real medicine.

Carolina Stamu, M.D.

A man who is years ahead of his time—laying the foundation for twenty-first century medicine.

Barry Sears, Ph.D. Author of The Zone and Mastering The Zone Pioneer in developing drug delivery sytems for cancer and heart patients.⁶⁵

So who is this doctor who cured cancer? ⁶⁶

William Keley Eidem ⁶⁷writes: “Emanuel Revici was born over a century ago, a century apart from this one, in the plains of a mountainous country that was also a kingdom, in a land without telephone or radio, but with a culture that rivals our own. On September 6, 1896, from that land of simplicity and royalty, of farmers and kings, in Bucharest, Romania, was born perhaps the greatest medical scientist this world has ever known. Some memories fade with the passage of a century of life. Still, there are a few that have stayed with Dr. Revici and that seem to have influenced his entire life. At the age of ninety-eight Dr. Revici told me about a few of them.

His father, Tullius Revici, M.D., was a physician whose practice ranged from members of the nobility to the local peasantry. Emanuel showed an early spark of interest in his father’s profession. “My father had a microscope. We started playing,” Dr. Revici would tell me. Because of Emanuel’s interest, Tullius and his son had many conversations about the practice of medicine. As a boy Emanuel seemed to need little sleep and would often stay up half the night. He sometimes watched curiously as his father would go out late at night to see patients. Once, when Emanuel was young, he waited for his father’s return and asked him how much he was paid for the long, late-night house call. Tullius told his son he had not charged the patient because the family had little money. It was a lesson Emanuel would remember and would put into practice during his entire professional career.

When Emanuel was ten, he told his father he wanted to be a physician. Tullius asked him why he would want to follow in his father’s footsteps. Emanuel told him, “I want to help people.” His father pushed him on his answer, “Is it because you also think you can make a good living?” “No, I want to help people, only that,” Emanuel answered. Tullius was finally satisfied, “I’m glad you answered this way. If you had told me you also wanted to make a lot of money, I would have been disappointed.”

At the age of twelve, Emanuel took on the task of writing four medical books about the human body. He said he stopped at the fifth book, which would have been about the brain, because he found it too difficult. His father told him he was too young to be writing about such things, although one might guess he was secretly pleased.

Emanuel’s apparent intelligence and his interest in medicine could not be denied for long, however. By the age of sixteen he began to attend the Bucharest School of Medicine—a full four years ahead of the average first-year student. Revici was pulled out of his second year of medical school to serve as a field doctor in what would become World War I. He saw many soldiers die. “The trenches were dug in a straight line,” he said, “so one shell killed many.”

Seventy-five years later Revici recounted a story of an event that would change his life. On a day like so many others, his squad traveled down a road with their horse-drawn ambulances. In addition to himself, his ambulance carried a medic and a wounded soldier. He called for the caravan to stop.

Lieutenant Revici climbed out and went off into the woods to relieve himself. Within seconds the group was attacked, and at least one shell hit his ambulance. Both men inside were killed, as was the man riding on top of the ambulance.

The two horses that were hitched to the ambulance were also killed in the shelling.

After Revici returned to Bucharest and the story was told, he was taken off this front-line detail and reassigned to the hospital—possibly because he was so young, or perhaps because his intelligence was recognized as something that should not be lost.

He found himself in trouble almost right away.

Revici, who specialized in bacteriology while in medical school, quickly realized that too-high a number of patients were dying from apparent infection.

He performed some pathological autopsies on a few of the dead and found that the cause of death was cholera, a condition that was believed to have been previously eradicated. His discovery did not sit well with certain higher-ups.

Fortunately, even at his early age, Revici had gained the respect of some of the more senior people at the hospital, including Professor D. Danielopolu, chairman of medicine and a member of the French Academy, who said, “I know Dr. Revici. His specialty is bacteriology. If he says it’s cholera, then that’s what it is.” Through further investigation, Revici was able to track down the probable source of the outbreak to a patient from a remote area who had come in contact with some refugees from Russia.

When the war ended, Revici returned to medical school, from where he would graduate at the top of his class in 1920. Because of his number-one class ranking, he was automatically offered a teaching position at the university. He accepted the offer and within a few years he would become an assistant professor there.⁶⁸

Revici also opened his own medical practice. His father’s habit of treating whoever needed his services would become a hallmark of Dr. Revici’s practice.

In seventy-four years as a practicing physician, he would never turn away any patient because he or she was too sick or too poor.

Like his father before him, his patients came from all walks of life.

At first his patients would include the farmers and villagers of Romania. His willingness to treat the poor would continue throughout his life.

Yet, like his father, the well-to-do also came to see him.

Years later he would treat more than three thousand drug addicts, most of whom were from Harlem. In the meantime, he also treated some of the world’s luminaries including Oscar winners Anthony Quinn and Gloria Swanson; the Broadway star Gertrude Lawrence; the Archbishop of Ephesus, Lorenzo Michelle DeValich; the Dalai Lama; the wife of the Russian ambassador to Mexico; and the sister of a close advisor to the president of France.

Yet as much as he loved his patients, he also had a deeply curious mind. Throughout most of his life he slept only two to four hours a night. During his waking hours he devoted himself to trying to find answers to the scientific questions that perplexed him.

As Dr. A. R. Salman, a former Revici associate, who is now the chief physician of Emerald Coast Hospital in Florida, would recently say, “He didn’t go out to movies or dance. He devoted seven days a week, all of his life to his patients, his family and his research.”

How Dr Emanuel Revici became aware of the role of linoleic and ^{alpha linolenic acid} as a cure for cancer

The incident that precipitated his lifelong work in cancer came from a most unlikely series of events.

During his time as a professor, Revici saw on the operating table a young, pregnant woman, surgically opened up, whose abdomen was full of cancer.

The surgeon closed her up, thinking she didn’t have long to live. Dr. Revici never expected to see her alive again.

Two years later, in 1928, the apparently healthy woman returned to see Revici with her small child.

Revici wondered how it was possible for the woman to still be alive. The mystery would not leave his mind. He thought and thought about it—a task he is very good at. Several patients have commented on Revici’s ability to literally submerge himself in their charts. He becomes quiet and looks slightly downward, sometimes closing his eyelids, as if he were constructing something in mid-air right in front of his eyes.

Whether he used the same approach to ponder the mystery of the pregnant woman is not known.

Still, the question that occurred to no one else became his primary interest.

He knew that neither exploratory surgery nor pregnancy by themselves would have a curative effect on the course of a malignant tumor, so he theorized about the possibility that her dramatic recovery was due to the simultaneous occurrence of both events.

He began to study the placenta and noticed that it was rich in fat-soluble products called lipids.

He then experimented with animals, testing different placental lipids to see if they would have any effect on the course of cancer.

Those lipids produced some tumor reductions for short periods of time, but the tumor growth would often return.

In other cases, the lipids produced an increase in tumor activity.

He went to the literature to learn what he could about lipids, but found that there was very little written about them.

That did not stop him, however. He devoted what spare time he could to the question—usually in the dead of night.

Meanwhile, he continued handling his professorial duties and caring for his patients in his successful medical practice.

Revici’s active mind would lead him in other directions as well.

Revici’s other ventures: Revoil

Dr. Emanuel Revici developed a method for purifying motor oil that was far superior to anything available at the time. The process was especially good for the higher purification requirements necessary to produce aviation quality oil. As Dr. Salman has said with awe, “The man knows some chemistry.”

He knew chemistry so well that he was offered the equivalent of five million dollars by an oil company for the patent.

Revici decided to hold on to the patent. With the help of relatives, a small oil refinery was started, “It cost us about six lei per liter, and we received fifty-six lei for it.” The new product was called “Revoil”.

Revici lost much of his income from his invention during the second World War.

With the Communist takeover of Romania after the war, he no longer received any income from it.

The Revoil process continues to be used today—to refine both aviation and automobile motor oils.

Paris from 1936

The income derived from Revoil gave Revici the freedom to go to Paris to further his cancer research. He left for Paris in 1936. He was followed by his wife, Dida, the following year. Their daughter, Nita, who had learned French while attending a Romanian boarding school, joined them in Paris in 1938 at the age of nine.

According to Nita, now a medical editor with a Ph.D. in physiology, “We were living in one spacious room. My father came home for dinner. He took me to school. It was quite wonderful. I had both my parents.”⁶⁹

From 1936 to 1941, following resettlement in France, he continued his studies at academic and hospital laboratories directed by prominent Parisian physicians.⁷⁰ The Pasteur Institute was the most important and prestigious medical center in the world at that time and today remains one of the world’s leading medical research institutes. The competition to get scientific papers published at the Institute was extremely high.

5 Papers published at the Pasteur Institute in 1937 brought instant fame to Emanuel Revici

In 1937 Revici submitted five papers on lipids and cancer to the Pasteur Institute with the hope that the Institute would consider publishing one of them. Revici’s summaries concerned novel observations on lipids and cancer.⁷¹All five were accepted—two in 1937 and three in 1938.

His reputation soared as a result, and he was called upon by numerous doctors to treat some of their most difficult cases. In the course of being invited to treat other physicians’ patients,

Revici was offered the French Legion of Honor. The offer came as a result of his reversing the cancer of the wife of an advisor to the president of France. Revici declined to accept the honor, because he felt that such honors were political in nature.

A second offer of a French Legion of Honor would come as well. Revici had turned over to the French government the patents to a number of his inventions with the idea that they were to be used in the fight against the invading Nazis. Once again, Revici declined the honor.⁷²

Revici’s Lab Accident, 1939

While Nita was away at a camp during the Summer of 1939, Revici had a serious lab accident, jabbing himself with a needle containing an aggressive virus. The virus settled in the part of Dr. Revici’s brain that controlled his breathing.

He was placed into an iron lung, and his chances for a complete recovery were dim. He rallied, however, and was released.

The illness has never entirely left Dr. Revici.

For the past twenty years he has developed pneumonia at least once a year, probably as a result of the lab accident. Fortunately, he has always had his own antiviral medicines with which to treat himself.

So far, the 100-year-old patient has pulled through each time. Dr. Salman reports of a time when Dr. Revici was in his mid-eighties and sick with pneumonia. Revici insisted that Dr. Salman give him an injection of one of the lipid medications.

Within 15 minutes he began to improve. After 24 hours Revici had completely recovered. ⁷³

Paris in the 30’s Revici’s Development of non-toxic lipid chemotherapy to treat cancer, pain and many other symptomsand diseases

He laid the groundwork for a transformation in medicine during his research at the Pasteur Institute in Paris in the 1930’s.

By observing the energetic properties of lipids in health and disease, Dr. Revici inventive non-toxic lipid chemotherapy that effectively treats pain and cancer, as well as many other symptoms and diseases. Omega-3-ALA and Omega-6-LA were the lipids he used. ⁷⁴

War years: Revici in The French Resistance against the German Occupation

As World War II loomed, French academic physicians encouraged him to continue his studies, occasionally requesting him to apply his laboratory findings to terminal cancer patients under their care. These therapeutic experiments, said one doctor, always resulted in relief of pain and often in tumor regression.⁷⁵

Twenty years after the Second World War, a member of the high command of the Resistance in southern France recalled

Dr. Revici’s clandestine service in the Underground: “Revici volunteered in our resistance in which we badly needed secret help. Revici risked his life doing such jobs. He could have been arrested any time…His wife would have been deported…I never forgot his quiet courage and the lives he saved.”

His service with the French Resistance during World War 11 obliged leaders of the Underground to provide him refuge from Hitler’s reign⁷⁶ outside of Europe. ⁷⁷

World War II aborted his French career. The first part of this series on Revici recounted his eleventh-hour escape from the German forces occupying the French capitol. (The Nazis were rounding up Jews in Paris for deportation to death camps. Revici, who was Jewish, had retained his Romanian citizenship, and Romania was fighting on Germany’s side.

Such “distinctions” would have counted for naught had the Nazis landed him in their nets.) Fleeing with his wife and daughter to Nice in Vichy, France, Revici bore with him letters of recommendation written on the eve of flight in March 1941.

Dr. Roger Leroux wrote: “Dr Revici has been working in my laboratory for two years. He is carrying on a program of very interesting research of a physiopathological nature on the metabolism of lipids. He has brought to this question several new ideas of the greatest interest. It is vital that his research be continued without interruption, for the results obtained by Dr. Revici open a multiplicity of new paths to research of all kinds, particularly in the field of cancer.” Leroux was Professor of Pathologic Anatomy at the Faculty of Medicine, University of Paris.

Dr. Chifoliau extolled Revici: “On several occasions, in cases of patients afflicted with grave surgical conditions, I requested the aid of Dr. Revici, who willingly applied to our patients the results of his laboratory research. The result obtained in most hopeless cases were always the amelioration of pain and quite often, the progressive disappearance of large tumors. Dr. Revici’s research must be continued and fostered, and may change the therapy of tumors completely.” Chifoliau was an Honored Member of the Hospitals of Paris and a Member of the Academy of Surgery of France.

Fellow leaders of the Underground sped Revici and his family out of Europe in the Fall of 1941.⁷⁸

Revici Opens a Free clinic in Mexico, 1942

Mexico agreed to entry visas, and by early 1942, the Revicis had resettled in Mexico City.

Encouraged by his friend Gaston Merry, Revici converted a modern 100-room hotel into a medical institute devoted to his lipid research. Formerly the European representative for E.I. Du Pont de Nemours, Merry was a chemical engineer who had grown interested in Revici’s study of lipids while both were in Paris. (Du Pont had long positioned itself in the business world as a multinational combine specializing in chemical research and manufacture.)

Revici’s Mexico City institute had 15 qualified physicians and chemists on staff, with 60 support personnel. Most of the doctors and chemists were Mexican, but several eminent European physicians, surgeons, and scientists also in refuge, signed on. He established and directed a free clinic, staffing it with fellow physicians-in-exile and local physicians. The facilities included a hospital equipped with the latest technology, a clinical lab, a research department with eight labs, a section for experiments on animals, and an outpatient clinic. ⁷⁹The clinic, which contained over 100 rooms, mainly attended to cancer patients.⁸⁰

Concentrating on Revici’s explorations of lipid metabolism and disease, the researchers studied sulfur⁸¹ incorporated into lipids for antibiotic use, fatty acids as factors in arteriosclerosis, and shock. The work on cancer focused on treatment of terminal cases with lipid extracts.⁸²

Revici’s Invitation to the US in 1946

In 1946, Dr. George Dick, dean of the medical school, Chicago University, invited Revici to carry forward his research in the U.S. ⁸³

Dr. George Dick (1881-1967), now you see me, now you don’t

George Frederick Dick (July 21, 1881 – October 10, 1967) was an American physician and bacteriologist best known for his work with scarlet fever.

Dick studied scarlet fever whilst serving the Army Medical Corps during World War I. Dick continued with his research into scarlet fever following the war, and in 1923, in collaboration with his wife Gladys Rowena Dick, managed to locate the cause of the disease in a toxin produced by a strain of Streptococcusbacteria. Using this, they were able to create an antitoxin for treatment and a non-toxic vaccine for immunization.

In 1933, Dick his wife were awarded the Cameron Prize for Therapeutics of the University of Edinburgh.

George Dick⁸⁴

He was a professor of clinical medicine at Rush Medical College, Chicago (1918–33), and then became the head of the department of medicine at the University of Chicago (1933–45).⁸⁵

This is odd. If Dr George Dick invited Revici in 1946 to come do research tocome to research at the University of Chicago, because he was already not the head of the department of medicine there then.

In recognition of both his assistance to the French Underground and the potential of his scientific discoveries, Sumner Welles, a high-level aid to President Franklin Roosevelt, arranged with the U.S. Consulate in Mexico to grant special visas to speed the entry of Revici and his family.⁸⁶

Mr. Welles, a diplomat, had served in the Roosevelt Administration as Undersecretary of State from 1937 to 1942.

The diplomat who arranged Revici’s coming to America, Benjamin Sumner Welles( 1892-1961)

Benjamin Sumner Welles (October 14, 1892 – September 24, 1961)[1]was an American government official and diplomat in the Foreign Service. He was a major foreign policy adviser to President ^{Franklin D. Roosevelt} and served as Under Secretary of State from 1936 to 1943, during Roosevelt’s presidency.

Born in New York City to a wealthy, well-connected political family, Welles graduated from Harvard College in 1914. He entered the Foreign Service at the advice of Franklin Roosevelt, who was a family friend. Welles was excited by Woodrow Wilson’s ideas about how American principles could reorder the international system based on liberal democracy, free-trade capitalism, international law, a league of nations, and an end to colonialism.

Welles specialized in Latin American diplomatic affairs and served several posts in Washington and in the field. President Calvin Coolidge distrusted Welles because of his divorce and private sex life. He left public service and from bases in his two mansions in the Washington area he wrote a book on the history of the Dominican Republic.

When Roosevelt was elected president in 1932, he put Welles in charge of Latin American affairs as Assistant Secretary of State for Latin American Affairs, Welles became heavily involved in negotiations that removed Cuban president Gerardo Machado from power and replaced him with rival Carlos Manuel de Céspedes y Quesada. He was later promoted to Under Secretary of State, in which role he continued to be active in Latin American issues, but also expanded into European affairs as World War II began in Europe in 1939.

In 1940, he issued the Welles Declaration which condemned Soviet occupation of the Baltic states and proved to be a minor point of contention among the Soviets and their Western allies once the U.S. entered the war in 1941. Welles used American power and his senior position to intrude into the domestic affairs of other countries, especially choosing leaders who supported American policies. After the fall of France, he downgraded French affairs because they no longer were a major power. Roosevelt relied on Welles much more than on the official Secretary of State, Cordell Hull, who became the enemy of Welles.

Welles was forced out of government service by Secretary Hull when it was revealed he had solicited two men for sex. Returning to private life, he continued to write books on foreign relations and became an advisor to media organizations. He was a target of the House Un-American Activities Committee during the post-war “red scare”, though he was never formally sanctioned. He died in New Jersey in 1961, survived by his third wife and several children

Benjamin Sumner Welles⁸⁷

Dr. George Dick resigned suddenly the next year⁸⁸, that’s what the Townsend letter says. But the next year would be 1947, while he already resigned in 1945.

After that Revici promptly accepted an invitation from physicians, businessmen, and civic leaders to found an experimental cancer clinic in New York City ⁸⁹. However, another source says he founded the Institute of Applied Biology himself after being stranded in the US.

New York Institute of Applied Biology 1947-1990, After 1990 Revici Life Sciences

The clinic, named the Institute of Applied Biology (IAB), opened later in 1947. He earned his medical license in New York by examination in the same year and maintained his dual career as a scientist and physician in New York City .Revici served as scientific director, a position he held until the Institute of Applied Biology ceased operations in 1990. After that he started Revici Life Sciences⁹⁰

In the US, Revici repeatedly tried to inform doctors about his research on lipids in physiopathology through peer-reviewed journals and scientific conferences, but elements in the medical establishment frustrated his efforts.   ⁹¹

Revici’s publishing Career

Revici had a flying start with his publishing career when this 5 reseacrh papers were published by the Louis Pasteur Instutute in 1937.

In the U.S. he was brutally sabotaged.

After some thirty years of research Dr Revici wrote a 772 page textbook: Research in Pathophysiology as Basis for Guided Chemotherapy, with Special Application to Cancer. ⁹²

He also authorized over thirty articles on the treatment of cancer.

Soon after he set up his free clinic in Mexico City, and from the moment he co-established the Institute of Applied Biology in N.Y. Revici sought to disseminate his theories and therapeutic results.⁹³

He published papers, often in co-authorship, in peer-reviewed journals.⁹⁴ He and his colleagues presented papers on different aspects of his research before scientific and medical organizations. ⁹⁵

These attempts to acquaint, the medical community with his studies at the Institute of Applied

Biology encountered resistance. In particular, correspondence and articles critical of his

method of cancer treatment, published in the Journal of the American Medical Association in 1945 and 1949, severely hindered wider circulation of information about him and damaged his capability to raise funds and operate normally. ⁹⁶

Revici claimed that the letter appearing in the Journal of the American Medical Association in 1945, warning against his Mexican clinic, contradicted favorable reports in the private correspondence of the signatories to the public letter; and the Journal of the American Medical Association did print a brief rebuttal from the Institute of Applied Biology pointing out that pivotal contradiction in 1949. ⁹⁷

The Institute of Applied Biology sued a local arm of the American Cancer Society, the Brooklyn Cancer Society, for libel in 1949 when the Brooklyn Cancer Society circulated an excerpt from the 1949 Journal of the American Medical Association piece. The suit was settled through arbitration the same year ⁹⁸, and the arbitrator, the president of the Medical Society of the State of New York, apparently impressed by the potential of Revici’s treatment, subsequently joined the Institute of Applied Biology’s board of directors.⁹⁹

In July, 1961, the D. Van Nostrand Co. brought out his 772-page textbook, Research in Physiopathology as Basis for Guided Chemotherapy, With Special Application to Cancer.¹⁰⁰

Teeming with ideas constituting the conceptual bases for his method of treatment (while mostly appending his experimental and clinical data as footnotes), the book summarized his life work from the mid-1920s through the 1950s.¹⁰¹

Release of Revici’s text in July of 1961 by a publishing house long known for the quality of its scientific books marks the high point in his efforts to convince the U.S. medical community of the value of his research; but in April of that same year, the American Cancer Society had placed him on its “unproven methods” list, and few physicians, researchers, or medical libraries purchased his text once it became available.¹⁰²

The American Cancer Society in the section about Revici in its literature on unproven methods of cancer management alludes to evaluations of his therapy at the University of Wisconsin and Chicago University in the mid-1940s.¹⁰³ The extant documentation from this period suggests the American Cancer Society has mistaken informal visits to his Mexican clinic by physicians associated with the University of Wisconsin for a formal investigation. The documentation also suggests that the American Cancer Society has attributed to Revici a test of his treatment at Chicago University that a colleague at this university appears to have

attempted. There is no contemporaneous evidence that Revici treated any patients there .¹⁰⁴

In its phrasing of actual negotiations with the National Research Council to evaluate him in the early 1950s, the American Cancer Society creates the impression that Revici and his associates at the Institute of Applied Biology refused to accept scientifically appropriate protocols for clinical trials.¹⁰⁵ The documents from parties on both sides, compared carefully, do not support the American Cancer Society’s interpretation of the collapse of Institute of Applied Biology/N.R.C. negotiations .¹⁰⁶

An unpublished description detailing Revici’s approach to cancer treatment, prepared by an associate in 1962, refers to a June meeting with the National Cancer Institute to explore a prospective National Cancer Institute evaluation .¹⁰⁷

The National Cancer Institute. presumably declined, because Revici next entered into discussions for a clinical appraisal by oncologists associated with two medical institutions in New York City. The protocols they worked out divided the oncologists into roughly even groups: one group to observe patients refractory to mainstream therapy treated by Revici and his staff at his inpatient facility; the other group to administer his treatment to similar patients at their own hospital. Each group was to publish their conclusions separately.

The 2-page summary report of this evaluation published in the Journal of the American Medical Association in November, 1965, stating that no benefit resulted from his treatment in the 33 patients studied, devastated him and undermined his support among the trustees of his inpatient facility.¹⁰⁸ He wrote a massive point-by-point rebuttal, profusely documented, which the Journal of the American Medical Association rejected (needing no reason beyond its length).

The Office of Technology Assessment (U.S. Congress), in its report about unconventional cancer treatments, condenses his rebuttal to its essential points, saying that he “presented summaries of patient records that he claimed showed objective responses to treatment, contradicting the C.A.G.’s interpretation of the same data,” and that “he noted, among other things, that several patients in the study had tumor remissions that the study group allegedly failed to recognize.”¹⁰⁹

The American Cancer Society, in a recent revision of its piece putting Revici on its unproven methods list, airs an objection by him omitted by the Office of Technology Assessment; “that he had been excluded from the group’s deliberations”.¹¹⁰ The documents, showing that the two groups violated the protocols by merging into one group and signing their names to one report, indicate that his contention seems solidly grounded (Francis Delafield Hospital, “Delafield Clinical Appraisal Protocol,” undated).

Now, 33 years after the appearance of the Clinical Appraisal Group’s summary, enough time has passed to note additional, currently more pertinent “flaws.” The C.A.G. trial fell far below the 11 gold standard” for such trials — a randomized, controlled, blinded study; it was a simple observational study, without controls, without randomization, without blinding of the evaluators to avoid bias. Moreover, besides being subject to bias, it occurred a generation ago! Which makes it, in the eyes of today’s literature-saturated researchers, a relic of “ancient” history.

In 1990, Seymour Brenner, a board-certified radiation oncologist: in private practice in New York City, presented a retrospective “best case study” of Revici’s cancer patients before the Office of Technology Assessment. The Office of Technology Assessment had convened a special meeting to enable critics of the final draft of its report on unconventional cancer treatments to suggest corrections. Brenner discussed 10 cases, documented by him (but not subjected to rigorous peer review), which he believed to be in remarkable remission; and the Office of Technology Assessment added his study to its section on evaluations of Revici (Office of Technology Assessment, 1990).

The Office of Technology Assessment report cites a much earlier evaluation warranting mention, an unpublished paper by Robert A. Ravich, MID, written while still a junior colleague of Revici at the Institute of Applied Biology. The paper summarizes the results in all 1,047 cases treated at the Institute of Applied Biology from its founding to 1955. The Office of Technology Assessment devotes considerable space to discussion of Ravich’s review, detailing his criteria for inclusion of patients, his classification of treatment groups according to Revici’s method for determining the predominant anabolic or catabolic imbalance present in each case, and his “tabulation” of objective and subjective responses to treatment (Office of Technology Assessment 199

0).

Since congressional establishment of the Office of Alternative Medicine in the National Institutes of Health (the O.A.M.) in 1992, the Office of Alternative Medicine in the National Institutes of Health and the Food and Drug Administration have cooperated in developing a protocol to test Revici’s therapeutic agents. Recently, the Center for Alternative Medicine at the University of Texas (Houston), signed on to assist.

These papers summarized observations Revici had made about the influence of lipids in pathological pain and cancer.

In 1943, a year after establishing his Institute in Mexico City, Revici sought to acquaint visiting US physicians with his findings, hoping they would assist in publishing them in peer-reviewed English-language journals.

His associate and friend Gaston Merry, in a personal letter dated September 5, 1945, aired his suspicion that the US doctors had intended to publish Revici’s findings as their own.

August 18, 1945 backstabbing letter, signed by those very same physicians

Perhaps with that aim in mind, these physicians took a glancing swipe at Revici. The Journal of the American Medical Association (JAMA), August 18, 1945, printed a letter signed by these physicians under the heading, “A Mexican Treatment For Cancer—A Warning.” The letter, not referring to Revici by name, disparaged both his theories and results.

“What seems to be behind the paper,” Gaston Merry wrote, “is the desire to work along the ideas of Revici and to claim the paternity of some of his ideas.

Physicians who spent time at Revici’s Mexican Clinic stole his ideas and passed them off as their own and signed the slanderous letter against Revici fro August 18 1945

A hint is given by an article published in Cancer Research on page 480 of the August number and called ‘The Effects of 3–4 Benzpyrene on the Auto Oxidation of Unsaturated Fatty Acids.’ It is signed by G.C. Meuller and H.P. Rusch, the latter being the doctor from Wisconsin who came at the end of 1943 to spend about 5 weeks here and who came again at the end of 1944.”

“His article,” continued Gaston Merry, “is the reproduction of an experiment made in Paris, the conclusions of which having been published at two or three occasions.

When Dr. Rusch was here in December 1943, I was present at the conversations as an interpreter, and Revici candidly discussed his findings at length, mentioning specifically the linoleic and alpha-linolenic-acids which are also the ones used by Dr. Rusch who took plenty of notes during the conversations.

As you know, according to Revici’s classification, 3–4 Benzpyrene is one of the first bodies to be considered as Lipobase.

Dr. Rusch does not go so far as to talk about Lipobases and Lipoacids but his method is a close reproduction of the technique mentioned by our friend.

I am afraid that all the notes taken 18 months ago and later will serve as subjects for publications which so far could not be made from here.”

Gaston Merry ended: “I guess the best thing would be to liquidate what we have here and have Revici working in a laboratory in the States with the proper help to repeat all his experiments in support of his theory and especially the suitable collaboration for writing up the publications. It is a great handicap for him that his English is too poor for writing the necessary articles. This is what we asked for when the Texas and Wisconsin gang came here but they acted deaf.”¹¹¹

1945 Revici tricked into going to the US

In 1945, Revici received an invitation by George Dick to come work at the University of Chicago. Lab assistant Gustave Freeman, a lab assistant at the Unversity of Chicago had arranged this invitation. However, George Dick resigned suddenly, and his successor was hostile to Revici and his methods.

Stranded in the US, Revici founded the Insititute of Applied Biology in 1947together with Urologist Abraham Ravich. Abraham Ravich’s son Robert joined them .

This will be discussed in more detail later.

From the moment Revici co-established the Institute of Applied Biology in Brooklyn, New York, in 1947, the Institute reported on its investigational programs.

Summaries of Revici’s findings prior to the opening of the Institute of Applied Biology appeared in booklet form, printed and bound in blue paper covers, with each booklet devoted to a single subject.

Itemizations of new or ongoing studies periodically circulated as mimeographed typescripts.

For example, “Report on the Research Conducted at the Institute of Applied Biology,” issued 10/15/48 by the Cancer Research and Hospital Foundation (the IAB’s funding arm), listed over 20 different experiments. “The fixation of oxygen, sulfur, and selenium in unsaturated fatty acids” was the second experiment in this itemization. The 21st experiment was “The influence of lipids in healing of tissue injured by radium emanation.”¹¹²

October 11 1948, Request from the US Navy for Revici’s Cure for radiation damage

Revici’s research on radiation injury had blipped onto the US Navy’s radar screen 18 months earlier. A letter from a Colonel Thomas G. Cassady, dated just four days before the Institute of Applied Biology report, confirmed the Navy’s interest: (Military scientists were testing nuclear weapons on isolated atolls in the Pacific Ocean in the late 1940s, seeking to protect servicemen on the battlefront from lethal radioactive fallout.)¹¹³

“I have had several conversations,” Cassady wrote, “at the Naval Medical Research Center at Bethesda, MD, regarding Dr. Revici…About a year-and-a-half ago …they had conversations with the Doctor. They were interested in his research work and offered him certain facilities…As well as I could, in my layman’s language, I told them of his further research in the matter in question. They will see him again as it is their policy to leave no stone unturned in seeking relief or a possible cure for the type of injury in which the Doctor has made some progress.¹¹⁴

Twice in the late 1940s, the Office of Naval Intelligence cleared Revici to work on this top-secret project. Twice he declined, preferring to work on radiation primarily in relation to the broad problem of cancer.

Between July 1950 and June 1951, three papers about Revici’s findings on lipids and radiation came to the attention of the clinical research community.

Abraham Ravich’s son, Robert Ravich, at the Institute of Applied Biology (fresh out of the College of Physicians & Surgeons, Columbia University), read a paper by Revici at the Sixth Annual Congress of Radiology in London on July 26, 1950. Titled “The Influence of Irradiation Upon Unsaturated Fatty Acids.”

This paper dwelt on abnormally conjugated lipids, which clearly fit Samuelsson’s description of leukotrienes published in 1987.¹¹⁵ 

Revici didn’t use the terms “leukotrienes” or “prostaglandins” here, but in later publications, he indicated the role these substances play in inflammation, and he attributed the high bioactivity of prostaglandins to a “twin formation which appears through the cyclization of arachidonic acid.”

Dr. Robert Ravich presented another paper by Revici (co-authored by Robert Ravich) before the American Association for the Advancement of Science in Cincinnati in December 1950.

The paper bore the title, “The Effect of n-Butanol in Sodium Salt Solutions Upon Shock and the Survival of Mice Exposed to Severe Thermal Burns.”¹¹⁶ Waldemar Kaempffert, a senior science writer for The New York Times, devoted a column to Ravich’s presentation in the March 4, 1951 issue of the Times, stressing the potential value of Revici’s findings on radiation injury should American cities be hit by A-bombs.¹¹⁷

“Fall-out” from a paper delivered by Leonard Goldman, MD, at a meeting of the American Medical Association in Atlantic City, NJ, in June 1951 marked the first documented instance of mainstream opposition to independent clinicians trying to follow Revici’s line of research.

Notice of Goldman’s study, titled the “Use of Lipids to Enhance the Effect of Roentgen Therapy in the Treatment of Pain from Advanced Cancer,” ¹¹⁸made its way into a dossier that the American Cancer Society (ACS) maintained on Revici.

The dossier was labeled, “Summary of information contained in the American Cancer Society, Inc.’s files concerning the Institute of Applied Biology and Dr. Emanuel Revici, as well as other persons concerned in the matter.”¹¹⁹ 

Here’s an entry about a memorandum from Dr. B. Aubrey Schneider of the American Cancer Society, who had heard Goldman’s paper, to Dr. Charles Cameron, scientific director of the national American Cancer Society: “In his memorandum to Dr. Cameron, Dr. Schneider adds that in a private conversation with Dr. George Cooper,

Director of the Virginia Division of the Society, he indicated that he was going to try out the Lipid therapy on some cases now under his care at the University of Virginia Hospital. A copy of Dr. Goldman’s paper is in the files.”

Goldman had reported on the palliative effects of Revici’s therapy.

He next proposed a trial of its therapeutic effects, requesting approval from the Institutional Review Board (IRB) at Queens General Hospital, where he served as a resident. Another entry from the American Cancer Society dossier on Revici picked up the story: “Early in January, Dr. Cameron received a phone call from Dr. Alfred Angrist, Pathologist at Queens General Hospital. Dr. Cameron prepared a memorandum which is in the files. Dr. Angrist felt that Dr. Revici exerted strong psychotherapeutic influences on patients and discussed his personal feelings, as Chairman of the Hospital Committee on Research and Publications, with regard to hospital approval of a paper on the Revici treatment by Dr. Goldman.

Because of Dr. Angrist’s strong ‘anti’ feelings, an ad hoc committee had been appointed to consider the particular paper, and Dr. Angrist felt that the committee’s membership had been stacked. At his request, Dr. Cameron suggested Drs. Gellhorn, Bodansky, and Schoenbach as additional committee members.”¹²⁰

Minutes from meetings of the Institute of Applied Biology’s board of directors in 1952 relate that the “restacked” IRB at Queens General denied Goldman approval. In 1986, Dr. Goldman addressed the Regents of the State of New York, in a written plea supporting Revici’s struggle with the Office of Professional Medical Conduct to remain in practice. He noted his early interest in Revici’s treatment, and—for the first time publicly – he disclosed that his studies on lipid therapy had cost him his residency privileges.

While the American Cancer Society and associated elements in mainstream medicine were helping to clip Dr. Goldman’s wings behind the scenes, The New York Times printed a feature on the Institute of Applied Biology in its December 2, 1952 issue.¹²¹ 

The writer, William L. Laurence, was probably the most distinguished science reporter at that time; the US had broken the news of the A-bombing of Hiroshima and Nagasaki under his byline. The first three paragraphs of Laurence’s report on the Institute of Applied Biology ran as follows:

Animal experiments and tests on patients in advanced stages of cancer were described last night by leaders in medicine as lending “strong support” to a new concept of malignant disease that may lead to a radically new approach to its ultimate control. The progress reports on the new methods, developed at the Institute of Applied Biology, Brooklyn, were presented at the fifth annual dinner of the Cancer Research and Hospital Foundation at the Waldorf-Astoria Hotel. More than 400 leaders in medicine and other professions, as well as leaders in industry and civic affairs, were present.

One of the reports was prepared by Dr. John Masterson of Brooklyn, former president of the Medical Society of the State of New York and a member of the House of Delegates of the American Medical Association. He is now attending the American Medical Association meeting at Denver and the report was read in his absence.

Other reports were presented by Dr. John M. Galbraith, past president of the Nassau County Medical Society; Dr. Emanuel Revici, scientific director of the Institute; and Dr. Robert Ravich, assistant director.

Laurence’s last paragraph, notes: “Prof. Jacques Maritain of the Institute of Advanced Study at Princeton, NJ, one of the world’s leading philosophers, is a director of the Cancer Research and Hospital Foundation, a non-profit organization to raise funds for the cancer research program of the Brooklyn Institution.”¹²²

By the mid-1950s, at least one of Revici’s associates believed a distinct pattern had become discernible in the reception of papers submitted to peer-reviewed journals by the Institute of Applied Biology.

In a letter to one of the Institute’s chief funders, dated 11/12/55, Robert Ravich recounted the publication history of an article he had co-authored with Revici, titled, “Antihemorrhagic Action of n-Butanol in Advanced Cancer” (Angiology, December 6, 1953).

Bear in mind that butanol – the higher sterol Revici gave to control bleeding in Resistance fighters in southern France – worked so well, it set the Nazis on its developer’s trail; in effect, it amounted to his “ticket” out of Europe. ¹²³

In the United States after the war, Revici had developed butanol for cancer patients too ill to stem internal hemorrhages surgically. Injected intravenously, it sped through the blood system to the site of a severed artery or vein, permanently constricting the muscle tissue circling the vessel at the rupture point.

The Revici-Ravich paper reported on two small series of patients, one group injected with butanol and the other, control arm, not given Revici’s antihemorrhagic agent. (Revici discovered the mechanism of action after publication.)

Ravich’s letter started with an assertion: “I told you that the Institute of Applied Biology had encountered a mysterious form of censorship whenever it attempted to have an article concerning cancer published in the regular channels. The following is a case history which bears out my statement.”

In short, Ravich’s case history of the butanol paper goes like this:

rejection in 1951 by Cancer (after a recommendation to accept by the reviewer); rejection in 1951 by the Journal of Laboratory and Clinical Medicine and the Journal of the National Cancer Institute; and rejections in 1953 in the original submission and resubmission to the New York State Journal of Medicine. The editors cited various reasons. Consultants didn’t think the paper represented a controlled clinical experiment (Cancer). The subject was not of sufficient interest to readers (Journal of Laboratory and Clinical Medicine). Not suitable for publication here: try a journal of a more general nature (Journal of the American Cancer Institute). It was doubtful that n-Butanol had any relation to the cessation of hemorrhage in the patients studied (New York State Journal of Medicine).

Dr. Ravich closed his letter with these paragraphs:

On August 12, 1953, the article was submitted to Angiology. It was accepted without comment and was published on December 6, 1953. Angiology is a journal with very limited circulation, and not one that is likely to be read by doctors interested in cancer or by general practitioners who might find the article of value. We have received requests for reprints from all over the country and the world and some interesting comments and observations.

The experience with this paper indicates beyond any question that the problem of publishing our work on cancer is not a simple one. Why this invisible form of censorship is permitted to exist in scientific and medical publications and how it operates are questions that I am not able to answer. But I do believe we are justified in saying, on the basis of such experiences, that the normal channels of publication have been closed to us and that we are therefore forced to take any other way that may be open, to get our findings before the medical and scientific public.

Then Ravich added a postscript, dredging up a wider, deeper history of attempts by Revici and the Institute of Applied Biology to publish in the peer-reviewed literature:

Every paper we have submitted on subjects outside the field of cancer has been accepted; every one concerned with cancer has been rejected. When four articles were submitted by Dr. Revici by title alone, for presentation at the International Cancer Congress in Paris in 1950, all of them were rejected. Only seven papers in all were rejected, and almost a thousand read. I learned from Dr. Oberling that they had been rejected because of the intervention of Dr. Rhoades and others in this country on the program committee.

He would have known the circumstances behind the rejection of Revici’s papers

Dr. Charles Oberling (1895-1960) Why was he so respected?

Dr. Charles Oberling (Metz, July 31 1895- Paris, March 11, 1960) ¹²⁴, a French academic physician who relocated in the US after World War II, was highly regarded by American oncologists.

Son of a railway employee, Charles Oberling was born on July 31, 1895, in Metz, a bustling garrison town in Alsace-Lorraine1. Despite his numerous trips to the United States, Iran, Germany and France, he remained, throughout his life, attached to his native city, “a strong city par excellence” 2. Schooled in Alsace-Lorraine, he naturally did all his studies in German. In 1913, he continued to study medicine in Strasbourg, obtaining his doctorate in medicine in 1919.

Dr. Charles Oberling
Having opted for French nationality, Oberling was admitted as an intern at the University of Strasbourg and became assistant to Professor Pierre Masson. He worked at the Institute of Pathological Anatomy until 1926. In 1928, Charles Oberling obtained a chair in Histology, Embryology and Pathological Anatomy at the Faculty of Medicine in Paris. He focuses his research on tumors of the nervous system and meninges. Back in Strasbourg in 1936, he headed the Institute of Bacteriology.

During the Second World War, the University of Strasbourg was relocated. At the end of 1939, on a proposal from the French authorities, Charles Oberling became hygiene advisor to the Iranian government.

Elected dean of the Tehran Faculty of Medicine soon after, he reorganized the university and studies.

From 1942 to 1944 he worked as a pathologist at Cooperstown Hospital in the United States, publishing The Riddle of Cancer, then returned to Tehran.

In 1948, Professor Oberling returned to France to head a cancer research institute for the CNRS.

He obtained a chair in oncology at the Faculty of Paris in 1949, then a chair in experimental medicine at the Collège de France. He was elected member of the section of biological sciences of the National Academy of Medicine..¹²⁵

Professor Charles Oberling, the famous French pathologist, was the pioneer in designing a new educational curriculum based on the modern programs in Iran.

He was introduced by French officials to reorganize the Faculty of Medicine of Tehran University.

In 1939, Oberling came to Iran and was appointed as the dean of the Faculty of medicine.

With the support of Iranian officials and his colleagues at medical school, he designed a new educational curriculum based on the modern programs, similar to those in medical schools of Europe, especially France.

He also equipped and redesigned Tehran hospitals for educational purposes and had them supervised by medical school authorities.

The other main goal of Professor Oberling in Iran was improvement of health standards by controlling the diseases and providing proper facilities for implementation of hygiene.

Professor Charles Oberling passed away in 1960 at the age of 65. He was vanquished by cancer, the enemy he had always fought. On his death, his colleague wrote: “Oberling was both a man of action and a humanist…he loved life…his warmth and enthusiasm won him a myriad of admires”. ¹²⁶

So why was Dr. Charles Oberling so respected?

These were his publications: ¹²⁷

Le système réticulo-endothélial, Paris: Masson, 1924.

• La maladie de Gaucher chez le nourrisson, Strasbourg: Imprimerie Alsacienne, 1927.
• Titres et travaux scientifiques du Dr Charles Oberling, Strasbourg: Impr. strasbourgeoise, 1928.
• Sur les troubles circulatoires angioneurotiques du poumon consécutifs à des lésions expérimentales des noyaux gris centraux de l’encéphale, A. Kallo, 1929.
• Les tumeurs des méninges, 1932.
• Précis d’anatomie pathologique, Paris: Masson et Cie, 1933.
• Leucémie et cancer: étude expérimentale, Paris: Masson, 1933-1934.
• Influence de la quinine et de ses dérivés sur la leucémie transmissible des poules, 1934.
• Les modalités de l’action cancérigène du 1-2 benzopyrène, Paris, 1935.
• La production expérimentale de tumeurs hypophysaires chez le rat, 1936.
• Hépatome de la clavicule, Paris: impr. Maretheux, 1936.
• Précis d’anatomie pathologique, Paris: Masson et Cie, 1942.
• Le problème du cancer, Montréal: Ed. de l’Arbre, 1942.
• (en)The riddle of cancer, New Haven: Yale University Press, 1944.
• L’organisation de l’enseignement médical en Iran, Téhéran, 1946.
• Précis d’anatomie pathologique, Paris: Masson et Cie, 1950.
• Leçon inaugurale, Paris, le17 janvier 1950, Faculté de médecine de Paris, Chaire de carcinologie, Paris : Masson, 1950.
• Le cancer, Paris: Gallimard, coll. «L’avenir de la science», 1954.
• Leçons inaugurales 19-28, 1955-1958, Pari: Collège de France, 1955-1958.
• Leçon inaugurale faite le vendredi 6 janvier 1956, Collège de France, Chaire de médecine expérimentale, Paris : Collège de France, imp. 1956.
• (de)Krebs: das Rätsel seiner Entstehung, Hamburg: Rowohlt, 19594.
• Néoplasies et cancers à virus, Paris : A. Legrand, 1961.

In collaboration:

• Recherches sur des greffes en série de tumeurs mammaires bénignes chez le rat, M. et P. Guérin; Paris : Masson, 1934.
• A propos de la transformation sarcomateuse des fibroadénomes mammaires transplantables du rat blanc, M. et P. Guérin, Paris : Masson, 1935.
• Recherches sur l’action cancérigène du 1,2 bensopyrène, par Ch. Oberling, M. et P. Guérin, Paris : Masson, 1936.
• Lipome transformable du rat provenant d’un adénolipome mammaire, M. et P. Guérin, Paris : Masson, 1936.
• Recherches physiologiques sur les levains minéraux à base d’alun, Georges Schaeffer, Georges Fontès, Éliane Le Breton, Charles Oberling, Lucien Thivolle, Vanne : impr. de Lafolye et J. de Lamarzelle, 1928.
• Abcès streptothricosiques du cerveau, par MM. P. Morin et Ch. Oberling, Société française d’imprimerie, 1930.
• Cancer du pancréas, M. Guérin, Paris : Gaston Doin & cie, 1931.
• Les fibro-adénomes mammaires greffables du rat blanc,: nouvelles recherches / par Ch. Oberling, M. Guérin et P. Guérin / Paris: Masson, 1937.
• Précis d’anatomie pathologique, / par Gustave Roussy, Roger Leroux et Charles Oberling / 2e édition / Paris : Masson et Cie, 1942.¹²⁸

So Oberling is well respected among oncologists, while he had no solution for cancer and died of it 64, and Revici was ignored, while he cured cancer and, in spite of all the sabotage he received, lived to be 101.

If you think that’s odd, listen to what kind of person the first Sloan Kettering director was, ”Dr”Cornelius Rhoades:

Dr Cornelius Rhoads, headed the chemical warfare devision of OSS (precurser to CIA), established the U.S. Army chemical weapons laboratories and maker of chemotherapy drug based on mustard gas that is still used today, as well as first director of Cancer Research Institute Sloan Kettering from 1945 to 1960

Guilty of unethical human experimentation, called patients “lab animals””that he and the other doctors had fun torturing” injecting them with cancer cells.

The Office of Strategic Services (OSS) was the intelligence agency of thenUnited States during World War II. The OSS was formed as an agency of the Joint Chiefs of Staff (JCS) to coordinate espionage activities behind enemy lines for all branches of the United States Armed Forces. Other OSS functions included the use of ^propaganda, subversion, and post-war planning. ¹²⁹

Dr. Cornelius Rhoads, the first major postwar director of Memorial Hospital in New York City (later, Memorial Sloan-Kettering Cancer Center), had headed the Chemical Warfare division of the Office of Strategic Services (OSS), the predecessor of the CIA. Rhoads had used his wartime post to experiment with mustard gas – a chemical agent used in World War I – on human cancer. The Congress to which Ravich referred was the International Union Against Cancer, whose president and editor on different occasions was Prof. Joseph Maisin of Belgium.

Cornelius Packard “Dusty” Rhoads (June 9, 1898 – August 13, 1959) was an American pathologist, oncologist, and hospital administrator who was involved in a racist an unethical human experimentation scandal and subsequent whitewashing in the 1930s.

Beginning in 1940, he served as director of Memorial Hospital for Cancer Research in New York, from 1945 was the first director of Sloan-Kettering Institute, and the first director of the combined Memorial Sloan–Kettering Cancer Center.

Cornelius P. Rhoads in Army uniform ¹³⁰

During his early years with the Rockefeller Institute in the 1930s, Rhoads specialized in anemia and leukemia, working for six months in Puerto Rico in 1932 as part of the Rockefeller Foundation International Health Board contingent.

During World War II, he worked for the United States Army helping to develop chemical weapons and set up research centers.

Research on mustard gas led to developments for its use in chemotherapy at Sloan Kettering.

In early 1932, a letter Rhoads had written in November 1931, which disparaged Puerto Ricans and makes claims (which he referred to later as jokes) he had intentionally injected cancer cells into his patients, was given by a lab assistant to Puerto Rican nationalist leader Pedro Albizu Campos.

This is what Rhoads wrote in his horrible, racist, genocidal, psychotic letter:

“ I can get a d*** fine job here and am tempted to take it. It would be ideal except for the Porto Ricans. They are beyond doubt the dirtiest, laziest, most degenerate and thievish race of men ever inhabiting this sphere. It makes you sick to inhabit the same island with them. They are even lower than Italians. What the island needs is not public health work but a tidal wave or something to totally exterminate the population. It might then be livable. I have done my best to further the process of extermination by killing off 8 and transplanting cancer into several more. The latter has not resulted in any fatalities so far… The matter of consideration for the patients’ welfare plays no role here — in fact all physicians take delight in the abuse and torture of the unfortunate subjects. “¹³¹

Pedro Albizu Campos.publicized the letter in the Puerto Rican and American media, which led to a scandal, an official investigation, and a US whitewashing campaign to protect Rhoads and, by extension, Rockefeller interests.

In the ensuing investigation, Rhoads defended himself, saying he had written his comments in anger and as a joke to a New York colleague.

Rhoads taught as a pathologist at Harvard and conducted research on disease processes.

In 1929, Rhoads joined the staff of the Rockefeller Institute for Medical Research, now Rockefeller University, where he worked for Simon Flexner. He was also staff pathologist at Rockefeller Hospital.

His early research interests included hematology and poliomyelitis. He worked at Rockefeller until 1939.

Rhoads was to assist Castle, and they established a base in San Juan at the Presbyterian Hospital. Rhoads corresponded often with Simon Flexner at the Rockefeller Institute in New York regarding his research and career interests. In Puerto Rico, the Rockefeller group had more than 200 patients; historian and ethicist Susan E. Lederer notes that, while referred to as patients, they were primarily clinical subjects whose conditions were studied to advance medical research. Because of the effects of anemia and the suspicion that tropical sprue was related to diet, Rhoads experimentally controlled patients’ diets.

Lederer notes that in letters from this time, Rhoads referred to his patients as “experimental ‘animals’.”

He wrote: “If they don’t develop something they certainly have the constitutions of oxen.”

Rhoads sought to experimentally induce the conditions he was studying in his patients rather than simply treat them. If they did develop tropical sprue, he could treat it with liver extract.

Rhoads established the U.S. Army chemical weapons laboratories in Utah, Maryland, and Panama. ¹³²

Rhoads’s Mustard gas based chemo therapy drug: mechlorethamineor Mustargen

Due to his casualty studies on mustard gas from an accident during the war in Italy, Rhoads became interested in its potential for cancer treatment.

Mustard gas or sulfur mustard is a chemical compound belonging to the sulfur-based family of cytotoxic and blister agent chemical warfare agents known as sulfur-mustards or mustard agents. … Mustard gas can form large blisters on exposed skin and in the lungs, often resulting in prolonged illness ending in death. ¹³³

For the rest of his life, his research interest was in developing chemotherapy for cancer treatment, but he served primarily as an administrator and scientific director at Memorial and Sloan-Kettering. From studies of mustard gas, he developed a drug called mechlorethamine or Mustargen. Its success in clinical trials during the war years was the basis for the development of the field of anti-cancer chemotherapy. Rhoads also became interested in total body irradiation, which led to early work on chemotherapy.¹³⁴

Mechlorethamine is a nitrogen mustard and antineoplastic agent that has been in clinical use for more than 60 years, given systemically in combination with other antineoplastic agents to treat Hodgkin disease, chronic leukemias, lung cancer and polycythemia vera ¹³⁵

Rhoads is the first director of Sloan Kettering Institute, 1945-1953, scientific director until 1960

In 1945, the Sloan-Kettering Institute was founded as a cancer research center, claiming to hope that an industrial approach to research would yield a cure.

It opened in 1948. While still director of Memorial, from 1945 until 1953 Rhoads also served as the first director of the Sloan-Kettering Institute.

He was “praised by Memorial for his ‘essential role in the evolution of the hospital into a modern medical center.'”¹³⁶

As director of Sloan-Kettering, he had oversight as well over research related to Department of Defense radiation experiments through 1954. For instance, that year, a Sloan-Kettering team began a multi-year study of “Post-Irradiation Syndrome in Humans.”¹³⁷

In 1953, Rhoads stepped back slightly, becoming scientific director of the newly merged Memorial Sloan–Kettering Cancer Center. He also continued as the scientific director of Sloan-Kettering operations. He also was an adviser to the United States Atomic Energy Commission regarding nuclear medicine. Some AEC funding supported Sloan-Kettering research into the use of iodine to transport radiation to cancer tumors.¹³⁸

Rhoads continued to serve as scientific director of the Memorial Sloan–Kettering Cancer Center until his death. He died of a coronary occlusion on August 13, 1959, inStonington, Connecticut.

In 1979, on the 20th anniversary of his death, the American Association for Cancer Research established the Cornelius P. Rhoads Memorial Prize in his honor, as an annual award to a promising young researcher.¹³⁹

Influence of Revici’s Institute of Applied Biology
Through the 1950s and early 1960s, research papers from the Institute of Applied Biology papers slipped into medical journals,²⁰ and The New York Times covered a few of the Institute of Applied Biology’s research advances, in areas where the papers or research didn’t concern Revici’s theories and therapeutic applications in cancer.²¹

From time to time, research on lipids and cancer not originating at the Institute of Applied Biology appeared in the scientific literature, focused on abnormal lipid metabolism, a prime Revici area of study.²²

Modern molecular biologists began publishing their insights into lipids in the 1980s, and virtually no clues in the English-language scientific literature pointed toward Revici as their predecessor.

Bengt Samuelsson‘s research on leukotrienes, which earned him a Nobel Prize in 1982, exemplifies independent confirmation of Revici’s groundbreaking experiments.

Samuelsson published his observations almost a generation after Revici had described these fatty acids in a paper read by a colleague at an international radiology conference in London in 1950.¹⁴⁰

By the 1980s, Revici had been a US resident (and naturalized citizen) for close to four decades, treating cancer patients at his New York City Institute of Applied Biology (IAB) since 1947 with compounds derived from his clinical research.

These agents, negligible in toxicity, included selenium in lipid bases and Omega-3-ALAand Omega-6-LA.

Unlike his scientific investigations, Revici’s medical applications quickly attracted the attention of establishment institutions, the American Medical Association (AMA) and the American Cancer Society (ACS) foremost among them.

False Attacks on Revici

The Journal of the American Medical Association (JAMA) published a joint letter in August 1945, warning about the treatment for cancer at the clinic that Revici had established in Mexico City in 1942.

The signers were US physicians who had visited the clinic between the fall of 1943 and the summer of 1945.

The Journal of the American Medical Association published a report by the American Medical Association Council on Pharmacy and Chemistry in 1949, which associated Revici’s method of cancer management with quackery and denigrated the research at the Institute of Applied Biology.

In 1949, the Institute of Applied Biology was located in Brooklyn, and the Brooklyn Cancer Committee of the American Cancer Society reprinted and distributed the American Medical Association report.

Revici and the Institute of Applied Biology sued the Brooklyn Cancer Committee for libel. The facts relating to the 1949Journal of the American Medical Association report slandering Revici and the Institute of Applied Biology and the consequent Institute of Applied Biology suit are provided in the account here.

Note that, since the 1940s, the American Cancer Society has been the prime source for stories spread among the medical profession about Revici.

The media, for the most part, has echoed the Society in reporting about him to the public—as they have done in general with unorthodox approaches to care branded heretical, in effect, by the American Cancer Society.

The most elaborate American Cancer Society version of Revici’s career appeared in the March/April 1989 issue of CA – A Cancer Journal For Clinicians, an American Cancer Society publication.

It spoke matter-of-factly of evaluations of his cancer therapy by US physicians in the mid-1940s. As this part of the Revici appreciation will show, all the tests of Revici’s therapy which the American Cancer Society represented in this piece as actually occurring in the 1940s turned out to be hearsay, misunderstandings of situations, or opinions expressed in correspondence.¹⁴¹

Revici’s Publications 1960’s

In 1961, D. Van Nostrand and Co. decided to distribute a text by Revici under its imprint. Research in Physiopathology as Basis of Guided Chemotherapy, With Special Application to Cancer ¹⁴²had been in various draft stages for several years: Institute of Applied Biology newsletters voiced news of its progress in the late 1950s.

Close to 800 pages in print, Revici’s monograph summed up his prolific findings from the mid-1920s through the 1950s.

When it undertook to bring out Revici’s monograph, D. Van Nostrand had been publishing scientific volumes from its main office in Princeton, NJ, since 1848. It had earned a solid reputation for quality. A letter from the president, Edward M. Crane, on June 8, 1961, spoke of the publishing firm’s “keen interest” in an “important and valuable book.”²³

Earlier that spring, in the March-April issue, Ca, a Journal for Clinicians had come out with a feature on Revici’s method of cancer control, characterizing it as “unproven.”

Crane, D. Van Nostrand’s president, in a telephone interview in the late 1980s (conducted by the writer), said he thought there was room at that time for another approach to cancer.

Revici had filled his book with explanations of his theories, with reports of experiments on their clinical application, as leads to follow and independently prove or disprove the efficacy of his therapy.

He viewed his method as a way to manage cancer that differed in critical particulars from standard therapy: his treatments were comparatively non-invasive, negligible in toxicity, and individually guided.

He also felt that the results of his treatment were equal or superior to the outcomes of treatments in common practice in a significant percentage of cases, especially in cases resistant to other approaches.

In blacklisting Revici’s method of cancer control, the American Cancer Society aimed to keep patients from his therapy.

To an incalculable extent, the Society succeeded.

There’s no telling how many of Revici’s medical insights might have proven of value, had clinicians been able to get hold of his text, to familiarize themselves with his method, to test his treatments in practice.

Most importantly, had the American Cancer Society not discouraged sales of his book, there’s no estimating the number of patients who might have benefited from the free circulation of his ideas.

Revici’s publications in the 70’ s

This publication was also to prove the near terminal event in his attempts to acquaint his peers with his clinical research: one paper on the narcotic addiction treatment Revici developed in the early 1970s appeared by invitation in a Canadian government journal on addictions in Quebec in 1973.

More False Attacks on Revici

The 1989 American Cancer Society piece also claimed that Revici demonstrated his method at the University of Chicago in 1946, trying it on 52 cancer patients with “no favorable effects” attributable to his treatment.

The Society’s source was an American Medical Association file. Who supplied this story to the American Medical Association awaits an airing of American Medical Association informants on Revici.

Indisputably, Revici was in Chicago in 1946—thanks to Gustave Freeman, an assistant professor of Medicine at the University of Chicago.

Gustave Freeman, an assistant professor of Medicine at the University of Chicago. Freeman had stumbled onto Revici in 1944 while serving as a major in the US Army in Mexico, where his duties involved official liaison with the Mexican government and research on controlling typhus. A lieutenant undergoing treatment at the Mexico City clinic had aroused his curiosity. Six times over two months, without prior notice, Freeman dropped into the clinic, speaking with Revici for many hours. (His fluency in Spanish gave him an edge over other US physicians appraising Revici’s research.)

On February 12, 1945, Freeman reported to Dr. George Dick, chief of the Department of Medicine, University of Chicago, that Revici seemed “properly scientific in his outlook.”

None of the American physicians investigating his clinic had discovered any unethical activities, including a San Antonio surgeon, Dudley Jackson, who had exposed cancer quacks for the US Public Health Service and was sending patients to the Mexican clinic.

Remarking that Revici’s approach was “so much more promising than anything that has appeared in the field of cancer,” Freeman urged Dr. Dick to offer adequate lab facilities and patients for a fair trial.

Dr. Dick extended an invitation.

Revici shuttered his Mexican institute, arranging for patients under treatment to continue, and drove by car with his family to Chicago.10 Visas ordered by a special wartime assistant to President Franklin Roosevelt, Sumner Welles, eased his entry into the US. (The visas, requested by commanders of the Resistance, recognized both Revici’s service with the French Underground and his promising cancer research.)

En route, Revici stopped overnight in San Antonio to pay respects to Dr. Dudley Jackson.

Jackson had been asked by Chauncey Leake to sign the 1945 Journal of the American Medical Association letter. Instrumental in founding the National Cancer Institute in 1937. Dr. Dudley Jackson had the political muscle to refuse.

A Loyal Friend of Revici’s: Dudley Jackson, Sr., 1890-1959

Dudley Jackson, Sr., cancer researcher and oncologist, was born in Eddy, Texas, on August 26, 1890, the son of Charles S. and Sallie (Wright) Jackson.

He received his early education in Brownwood public schools and attended Daniel Baker College before graduating from the University of Texas Medical Branch in 1917.

Jackson served an internship as a first lieutenant in the United States Army and was stationed both in the United States and overseas.

After his discharge in 1919 he opened a medical practice in San Antonio, specializing in cancer, and remained there until his death. With the help of legislation introduced by his cousin, Representative  Maury Maverick, Sr., Jackson was instrumental in founding the National Institute of Cancer.

He also promoted state legislation that established a state cancer institute and led to the development of the M. D. Anderson Hospital and Tumor Institute in Houston (now the University of Texas M.D. Anderson Cancer Center).

Jackson was a member of the Bexar County Medical Society, of which he was president in 1932.

He was also a member of the American Medical Association, Texas Medical Association, Texas Surgical Society, Southern Medical Association, and American Academy-International of Medicine.

He was a fellow of the American College of Surgeons and International College of Surgeons.

In 1954 he received the medal of the American Cancer Society and a certificate of merit from the society’s Texas division.

He was also the holder of a Walter Reed Society award for experiments in cancer, in which he transplanted living cancer cells into his own body in order to disprove the theory that cancer is contagious.

Noted for his willingness to treat cancer patients regardless of their race or their ability to pay, Jackson helped organize the Pan American Cancer Foundation, a group dedicated to the care of cancer patients in the southwestern United States and Mexico who could not afford treatment.

Jackson married Dr. Martha Nell Beal of Bertram on October 5, 1919, in Beaumont. They had two children.

He died of acute coronary occlusion on July 25, 1959. ¹⁴³

Revici’s attacker Chauncey Depew Leake, 1896-1978

Chauncey Depew Leak (September 5, 1896 – January 11, 1978) was an American pharmacologist, medical historian and ethicist. Leake received a bachelor’s degree with majors in biology, chemistry, and philosophy from Princeton University. He received his M.S. (1920) and Ph.D. (1923) from the University of Wisconsin in pharmacology and physiology

Leake was born in Elizabeth, New Jersey. At age 10, he was treated by the ophthalmologist Karl Koller.

Leake married the microbiologist Elisabeth Wilson in 1921, and they collaborated for many years. They had two sons and remained married until her death in 1977.

Leake discovered the anesthetic divinyl ether. One of his publications was a translation of the 1628 physiological work De motu cordis (On the Motion of the Heart) from Latin to English. Leake became a fulltime university administrator from 1942, first at the University of Texas and from 1962 at Ohio State University.

In 1973, Leake was one of the signers of the Humanist Manifesto II.

He was awarded the UCSF medal in 1975.

A collection of his papers is held at the National Library of Medicine in Bethesda, Maryland.¹⁴⁴

Leake and Fishbein¹⁴⁵

Confirming Revici’s suspicion that Leake had authored the Journal of the American Medical Association warning, Jackson added an intriguing bit of information.

Leake, he said, had been inspired by Cornelius Rhoads, head of the chemical warfare division of the Office of Strategic Services during World War II.

Postwar director of Memorial Hospital in New York City, Rhoads had used his military position to test deadly chemical agents as chemotherapy for cancer.

Shortly after Revici’s arrival in Chicago, Dr. Dick’s term as dean expired.

The new dean, unsympathetic to Revici, forbade him to treat patients at the university hospital.

Shelved in Chicago, Revici interviewed several doctors in the eastern US interested in cancer, choosing Abraham Ravich, a urologist with a large practice in Brooklyn, New York.

Revici’s co worker Abraham Ravich (1899)

Abraham Ravich, (Slonim, Poland.June 10, 1899) the Doctor Emanuel Revici chose to work with,was a Polish, American urologist.

He was the first to report on transmissible virus in prostate, cervix and bladder cancer asvenereal infection, and circumcision of new born males to prevent such cancers, also on significant role of renal vein compression by intra-renal pelvis in production of essential hypertension. Named honorary surgeon Honor Legion New York City Police Department.¹⁴⁶

Abraham Ravich¹⁴⁷ quickly convinced prominent local physicians, businessmen, educators, judges, and attorneys to back Revici’s research.

In March 1947, this group chartered two non-profit organizations; the Institute of Applied Biology (IAB), and the Cancer Research and Hospital Foundation.

Dr. Ravich was named director of the Institute of Applied Biology; Revici was named the scientific director (a position he held until 1990).

Dr. Gustave Freeman resigned from Chicago University and moved to Brooklyn to work alongside Revici.

Abraham Ravich’s son Robert, fresh out of the College of Physicians and Surgeons, Columbia University, also threw in his lot with Revici .¹⁴⁸

Turn coat Gustave Freeman (July 3, 1909-September 16, 1997) ¹⁴⁹

The only open access article I could find on Gustave Freeman was this obituary¹⁵⁰:

In April 1947, Gustave Freeman sent a detailed letter to an associate editor of the Journal of the American Medical Association, providing information on Revici and the nature of the Institute of Applied Biology’s clinical research. Most likely,

Freeman was responding to an American Medical Association request for background on Revici, because his letter touched on the story about Revici testing his method in Chicago.

Freeman told the editor that conditions and facilities didn’t permit Revici to treat any patients at the University of Chicago hospital.

Through the Freedom of Information Act, Marcus A. Cohen from the Townsend Letter¹⁵¹ obtained an FBI dossier on Revici in the late 1980s. Consisting of investigative and surveillance reports dating between the late 1950s and mid-1960s, it indicated that the FBI had cleared Revici, but most pages were unreadable, blacked out with “Top Secret” stamped at the top.

A deep wartime friendship between Revici and Constantin Omansky, Soviet Ambassador to Mexico, may have sparked the Bureau’s concern, putting agents on his postwar trail to snoop for residual ties with the Communist bloc in Eastern Europe.

On several pages, one can make out that an agent checked Revici’s medical activities in Chicago, finding no trace of him in the university hospital records.

Four years after the 1945 warning about Revici’s treatment in the Journal of the American Medical Association, bad publicity lingered as a major “stumbling block” to fundraising.

But the “highly ethical conduct of the research and the favorable results obtained” in terminal cancer cases at the Institute of Applied Biology were gradually dispersing the murky cloud over Revici created by that public statement.

Then, on January 8, 1949, the Journal of the American Medical Association ran a report by the American Medical Association Council on Pharmacy and Chemistry, headed “Cancer and the Need for Facts.”

The report named various individuals and groups as charlatans and purveyors of quackery, Revici and the Institute of Applied Biology among them.

The sole basis for including Revici appeared to be the 1945 Journal of the American Medical Association’s warning.

A number of organizations widely propagated the American Medical Association report, the American Cancer Society and the Consumers’ Union in the lead.

The report blasted the Institute of Applied Biology’s hopes of getting grants from the National Cancer Institute.

The president of the local American Cancer Society chapter, the Brooklyn Cancer Committee (BCC), reprinted the section on Revici and distributed the excerpt.

Subsequently, the Visiting Nurse Association refused to service Institute of Applied Biology ambulatory cases, and the county medical society barred the Institute of Applied Biology from using the society’s auditorium to defend its research before the medical profession.

Of course, lay members of the Institute of Applied Biology experienced extreme difficulty in collecting funds to support lab and clinical programs.

To protect their reputations, the lay sponsors of the Institute of Applied Biology demanded legal action, first against the local arm of the American Cancer Society, next against the American Medical Association .

A suit for libel was soon filed against the Brooklyn Cancer Committee and its president.

A libel suit against the American Medical Association, the laymen decided, would be too costly and difficult, so they abandoned the idea. The suit against the Brooklyn Cancer Committee never proceeded to trial.

Dr. John Masterson, president of the Medical Society of the State of New York, intervened, called the parties to a conference over which he presided, and issued a statement agreed to by all parties.

The Brooklyn Cancer Committee declared it never authorized or knew in advance about the reprint and its distribution, disavowed the letter by its president accompanying the reprint, and disavowed any slanderous inferences in the reprint and letter.

The Brooklyn Cancer Committee president acknowledged that he had acted on his own, regretted his action, and also disavowed the contents of the reprint, his letter, and libelous inferences in both.

All parties agreed that the section on Revici and the Institute of Applied Biology in the American Medical Association report was unjustified. Revici and the I Institute of Applied Biology withdrew their suit.

In the near aftermath, the Journal of the American Medical Association published a letter from Dr. Abraham Ravich, Institute of Applied Biology director, in its July 9, 1949 issue.

The letter began: “An article entitled ‘Cancer and the Need for Facts’ that appeared in The Journal (January 8, p. 93) contained a number of unwarranted statements derogatory to the research of Dr. Emanuel Revici and the Institute of Applied Biology.

These statements were based on a correspondence item published in The Journal on Aug. 18, 1945 (p. 1186).

We have in our possession and submit conclusive documentary evidence from a majority of these signers that completely contradicts their published unfavorable correspondence.

Accordingly, the statements that appeared in The Journal were without justification if based on these alleged facts.”¹⁵²

Neither the American Medical Association nor the American Cancer Society has ever coupled the 1945 letter warning against Revici’s Mexican clinic or the 1949 report by the American Medical Association Council on Pharmacy and Chemistry with this Institute of Applied Biology letter in their presentations questioning the efficacy of Revici’s therapeutic method.

Nor have the American Medical Association and American Cancer Society ever referred to the out-of-court settlement of the suit against the Brooklyn Cancer Committee that vindicated Revici and the Institute of Applied Biology.

There was another development in the aftermath of the suit against the Brooklyn Cancer Committee, which neither the American Medical Association nor the American Cancer Society has ever disclosed: impressed by the treatment approach and results at the Institute of Applied Biology, Dr. John Masterson became a member of the Institute of Applied Biology’s board of directors.¹⁵³

Dr. Revici remained embattled with the New York State health authorities for years and his medical license was revoked in 1993 at the age of 96. ¹⁵⁴

Revici’s Legal battles

The last two decades of his life enmeshed Revici in desperate battles to remain in practice.

He had survived the Clinical Appraisal Group’s evaluation in 1965, suffering a drastic blow to his reputation.

In the early 1970s, he had survived temporary suspension from the Medicaid program and a threat by the New York City health commissioner to prosecute him for administering allegedly unapproved compounds to detoxify some 3,000 drugs addicts.¹⁵⁵

Then, in November 1983 and again in January 1984, the deadliest attacks ever mounted against him commenced in the federal court and before the Office of Professional Medical Conduct.¹⁵⁶

In the court, he faced two malpractice suits, the first major negligence actions against him in 63 years of continuous practice.

He faced charges of gross negligence and gross incompetence (to cite the gravest of the charges, which basically reduce to departures from community standards resulting in claims of injury to patients — the simple definition of medical malpractice in negligence law).

Each proceeding could oust him from practice and close the Institute of Applied Biology.

Fourteen years of keeping, losing, and regaining his license in the State proceedings passed with an instrumental role played by his patients in saving the license.

Many victories were won by Revici in court.

The cases went to trial before juries, and in both cases the juries returned verdicts against him and awarded damages in monetary amounts totally beyond his capability to pay.

His attorneys filed appeals with the appellate court, and the appellate opinions reversed the lower court verdicts, remanding both cases for retrial.¹⁵⁷

The second case proceeded to retrial, and the jury verdict this time was for Revici.¹⁵⁸

The reason for reversal in each case was the same.

The appellate justices ruled that the lower court judges had failed to instruct the juries to consider whether the patients had expressly assumed the risk of treatment that departed from community standards.

The appellate rulings set a legal precedent, “Express Assumption of Risk” (technically speaking, an affirmative defense).

Under this precedent, if a defendant physician proves to a jury that a patient expressly assumed the risk of unconventional care, this bars recovery of any damages. To quote the appellate opinion in the first case:

‘Appellees contend that it is against public policy for one expressly to assume the risk of medical malpractice and thereby dissolve the physician’s duty to treat a patient according to community standards. We first note that the ‘public policy’ referred to … is defined solely by statute … and appellant points to no statute imposing limitations upon such express agreements.

Moreover, we see no reason why a patient should not be allowed to make an informed decision to go outside currently approved medical methods in search of an unconventional treatment

While a patient should be encouraged to exercise care for his own safety, we believe that an informed decision to avoid surgery and conventional therapy is within the patient’s’ right to determine what shall be done with his own body* ¹⁵⁹.

The two sentences that end this quote firmly place a significant development in the judicial branch of government, a matter of relatively narrow interest, into a much more general trend toward liberalization of attitudes about the risks patients (and the public) may take in choices affecting health.

This trend is discernible in actions and policies of the legislative and executive branches of government¹⁶⁰

It is traceable in medicine, where mainly the patient-centered school of outcomes research supplies impetus ¹⁶¹, and where increasing use of modem electronic communications devices tends to foster it (Silberg, et a], 1997).

The trend has been growing noticeable in these areas at different rates of progression, but its affect in common has been to expand the therapeutic options available to patients, especially for alternatives to mainstream care. Revici’s malpractice cases make a signal, historically secure contribution to this trend.

Reflecting on his life, on the obstacles he encountered in advancing his career and striving to earn recognition as a seminal figure in 20th-century medical science, certain questions arise about his temperament, about the ways he conducted research and applied laboratory findings to clinical practice. In short, how much did the personal factor count in building resistance to his theories and method of treatment? In precipitating the trials that buffeted him mercilessy toward the end of his days?

His approach to research was traditional: observation first, next hypothesis, then experiment. Theory seems to have appealed to him more than experimentation did. (He repeated experiments to confirm his hypotheses and data, but as soon as his experiments convinced him that he was correct, he wasted no time repeating them again.) Still, he clearly realized that both weighed equally in discovering and perfecting treatment.¹⁶²

Temperamentally, though, Revici had little tolerance for the time generally required to bring new treatments from breakthroughs in the laboratory to approval by the Food and Drug Administration.

He felt very strongly that gravely ill patients whose conditions were resistant to accepted modes of therapy could not wait for the approval process to run its usual dilatory course.

Once his own careful experiments confirmed to him that a therapeutic agent he developed was safe and effective, he gave it to patients regardless of regulatory agency policy.

Recovery, or relief for his patients was his primary, overriding rule.

The medical community and regulatory agencies, of course, adhere to a different, opposing rule, so his stubborn insistence in guiding his clinical practice in accord with his rule was likely to engender suspicion, hostility, and eventually administrative investigation and civil prosecution.

Independent validations of Revici’s findings about lipid structure and function have begun to accumulate over the past 20 years.

The section on his scientific discoveries in this article singles him out as the first medical scientist to elucidate the bioactivity of leukotrienes, the first to develop a safe, effective means of lipid transport.

Certainly, he pioneered in the use of selenium in a virtually non-toxic form to treat cancer¹⁶³ It now also appears that he predated his peers in administering Omega-3-ALAto shrink tumors.¹⁶⁴

When the Office of Professional Medical Conduct succeeded in revoking his license, on charges of probation violation amounting to inadequate record keeping (New York. State Health Department, 1993), they severed the ties to treatment and patients that had challenged him intellectually and nourished him emotionally throughout his career.

Dr. Korin took over until he passed away. It was run for a while by Dr. Joseph Carozzi and is now run by Dr. Revici’s grandson.

They use fatty acids and sterols, enzymes, high-dose selenium, dietary changes, and a “biologically guided” nontoxic chemotherapy.

He recommends not taking high dose vitamins without checking how these shift the body’s acid/alkaline balance. ¹⁶⁵

Late in life, reflecting on his Parisian period, he confided to friends that he never would have left France were it not for World War II.¹⁶⁶

I think he also would probably have been better off if he had stayed in Mexico.

Revici’s publications¹⁶⁷

220. REVICI, E.: Oxybiotic imbalances in biology. Role of lipids. Monaco Mediterranee Med. 8:1, 1941 (extra supplement). STOOPEN, E.: Action of fundamental lipids upon the reduction index of urine. Rev. Med. Pasteur 15:22, 1942.

221. REVICI, E., and LA BURT, H. A.: Observations on a new approach to the biological aspect of mental diseases. Abstract in 13th Ann. Report, Creedmoor State Hosp., 1948.

222. OROZCO, C. F.: The Revici reaction. Thesis, Univ. of Guadalajara, Mexico, 1943.

THEILER, R.: Concerning the Revici reaction in the urine. Thesis, Faculty of Medicine of Paris, 1940.

223. REVICI, E., HUESCA MEJIA, C, and RAVICH, R. A.: The measurement of the pH of experimentally produced wounds as a method for the study of abnormal foci. Bull. Inst. Appl. Biol. 1:73, 1949. REVICI, E.: The influence of irradiation upon unsaturated fatty acids. Presented at 6th International Congress of Radiology, London, July, 1950.

231. TASKIER, E. F., REVICI, E., and WILLHE1M, R.: Measure of adrenal defense against various fatty acids. 136th Meeting, Am. Chem. Soc., Sept., 1959.

237. REVICI, E., and RAVICH, R.: Surface tension of urine in old age. Geriatrics 9:386, 1954.

243. REVICI, E.: Some general considerations of the role of lipids in blood physiology. Presented at the Gordon Research Conference, Kimball Academy, Meriden, New Hampshire, June, 1955.

244. REVICI, E.: Studies on paroxysmal hemoglobinuria. Rev. Med. Pasteur 15:12, 1942.

247. WILLHEIM. R., REVICI, E., and AUBER. M.: Further experiments concerning the lytic power of blood serum against ascites tumor cells. Fed. Proc. 18, No. 2374, 1959.

326. REVICI, E.: The role of biological imbalances in physiopathology and therapy. Rev. Med. Pasteur, 15:133, 1942. ¹⁶⁸

Publications on Revici

October 18, 1965

Treatment of Cancer by the Method of Revici

David Lyall, MD; M. Stephen Schwartz, MD; Frederic P. Herter, MD; Perry B. Hudson, MD; Jane C. Wright, MD; Charles W. Findlay, MD; John M. Galbraith, MD; Arthur Purdy Stout, MD; C. D. Haagensen, MD

Author Affiliations

JAMA. 1965;194(3):279-280. doi:10.1001/jama.1965.03090160057014

Summary

Emanuel Revici, MD was a Romanian-born physician who had traversed the spectrum of human health, chemistry, lipids and physiology in ways never previously seen. Having emerged during the boom of quantum physics during the early and mid-20th century,

Dr. Revici’s 77 years of clinical practice was inspired by Albert Einstein and quantum theory.

Einstein is attributed as stating: [Revici is] “the greatest mind I had ever met.”

Few have ever heard of Emanuel Revici, MD, yet his discoveries and theories continue to astonish those with an interest in his revolutionary concepts.

Revici’s work is most known for his chemistry of lipids, and the study of various elements and lipids on cell membrane activity. Many of Revici’s discoveries had pre-dated medical science’s recognition by as much as 100 years.

Chronology

• September 6, 1896 Emanuel Revici is Born in Bucharest, Romania, to Tullia Revici, also a doctor, who helps people for free if they don’t have enough money, but who has such a good reputation that well kown people from far and wide come to him for help.
• 1898 Emanuel Revici tells his father he wants to be a doctor himself and writes an anatomy. Tullia is relieved he wants to do it to help people, not for the money.
• -1912 E.R. Starts medica school at age 16 and specializes in bacteriology.
• -1914 E.R. Pulled out of sceond year of medical school to become a field doctor in what was to become World War I. He identifies and recognises the culprit of a cholera epidemic and is deeply respected.
• 1920 Emanuel Revici Graduates from Medical School from the University of Bucharest at the top of his class, summa cum laude. Licensed to practice medicine and surgery in Romania. and opens a medical practice, where he, like his father, treats everyone.
• 1920 Revici Maintains a private practice until 1936. He also conducts research in major European medical centers including the Pasteur Institute. Makes his first discoveries involving lipids and cancer.
• 1926 the event that changed his life and brought him on the path of lipid therapy for cancer: a pregnant women full of cancer in her abdomen was operated on. He hadn’texpected her to live long, but 2 years later she was completely healthy, and so was her child. Revici reasoned that this must have to do with the large amount of lipids in the placenta and started testing animals with them. He noticed that some lipids stop tumor growth, and others induced, and through experimentation
• Between 1926and 1936 Dr. Emanuel Revici developed a method for purifying motor oil that was far superior to anything available at the time. The process was especially good for the higher purification requirements necessary to produce aviation quality oil. As Dr. Salman has said with awe, “The man knows some chemistry.” He is offered 5 million dollars for the patent, but decides to hold on to it, and sets up a small refinary as a familt business. With the Communist takeover of Romania after World War II, Revici no longer received any income from it. The Revoil process continues to be used today—to refine both aviation and automobile motor oils.
• Revici marries Dida and in 1929 they have a daughter, Nita.
• 1936 Thanks to the funds from Revoil, Revici is able to relocate to Paris. There he continues his clinical research on lipids and pathological conditions.
• 1937 The Pasteur Institute deposits 5 papers submitted by Revici on lipids in pathological pain and cancer in the National Academy of Science (France), giivng revici instant fame.
• 1938 Revici reverses the cancer of the wife of an advisor to the president of France. Revici is offered the French Legion of Honor which he declines. It is the first of two Legion of Honor Awards he declined. The second was in 1939 which he was offered because Revici had turned over to the French government the patents to a number of his inventions with the idea that they were to be used in the fight against the invading Nazis
• 1941: Because of the rounding up of the jews in Paris, fleeing with his wife and daughter to Nice in Vichy, France, Revici bore with him letters of recommendation written on the eve of flight in March 1941.
  
  Dr. Roger Leroux wrote: “Dr Revici has been working in my laboratory for two years. He is carrying on a program of very interesting research of a physiopathological nature on the metabolism of lipids. He has brought to this question several new ideas of the greatest interest. It is vital that his research be continued without interruption, for the results obtained by Dr. Revici open a multiplicity of new paths to research of all kinds, particularly in the field of cancer.” Leroux was Professor of Pathologic Anatomy at the Faculty of Medicine, University of Paris.
  
  Dr. Chifoliau extolled Revici: “On several occasions, in cases of patients afflicted with grave surgical conditions, I requested the aid of Dr. Revici, who willingly applied to our patients the results of his laboratory research. The result obtained in most hopeless cases were always the amelioration of pain and quite often, the progressive disappearance of large tumors. Dr. Revici’s research must be continued and fostered, and may change the therapy of tumors completely.” Chifoliau was an Honored Member of the Hospitals of Paris and a Member of the Academy of Surgery of France.
• Fellow leaders of the Underground sped Revici and his family out of Europe in the Fall of 1941.¹⁶⁹
• 1941 Revici is forced to flee to Mexico because of his medical aid to the French Resistance.
• 1941-1946 With his friend Gaston Merry Revici founds the first Instituto de Biologia Aplicada (IBA). As in Paris, his reputation grows and many physicians from the United States travel to the IBA to observe his work firsthand. None of the American physicians investigating his clinic had discovered any unethical activities, including a San Antonio surgeon, Dudley Jackson, who had exposed cancer quacks for the US Public Health Service and was sending patients to the Mexican clinic. He successfully treats the cancer condition of the wife of the ambassador to Mexico from the USSR, then an ally. As a result he is offered the Stalin Decoration by Molotov, along with the sum of $50,000 and the chance to have his own institute in the Crimea. Revici declines the offer.
• 1945 Cornelius Rhoades, OSS, f head of chemical warfar, becomes the first director of Sloan Kettering, a Cancer research centre aimed at nuclear Cancer treatments. Cornelius Rhoades develops a chemo drug based on mustard gas. OSS is the precurser to the CIA. Subversive activities against foreign powers isits specialty.
• 1945 One of the Doctors visiting Revici is Gustave Freeman, Laboratory Assistant to the University of Chicago school of Medicine, who is at that moment a leuitenant of the US army, stationed in Mexico. He arranges for Revici to be invited to the University of Chicago. On February 12, 1945, Freeman reported to Dr. George Dick, chief of the Department of Medicine, University of Chicago, that Revici seemed “properly scientific in his outlook.”Revici is invited by the chairman of the Medical Department, University of Chicago, George Dick. to forward his research.
• August 18, 1945 An unexpected setback to Revici’s career occurs when the highly influential.the Journal of American Medicine publishes a letter undermining Revici’s work in Mexico. It is signed by 50 doctors who have visited Ravici at the clinic, and who went on to steal his ideas. Leake was the author of the letter. He was an admirer of Rhoades.
• 1945 Revici’s entry into the U.S. was facilitated by Sumner Welles, an aid to President Roosevelt, in recognition for his work with the French Resistance and the beneficial potential of his therapeutic methods.
• 1945 En route, Revici stopped overnight in San Antonio to pay respects to Dr. Dudley Jackson. Jackson had been asked by Chauncey Leake to sign the 1945 Journal of the American Medical Association letter. Instrumental in founding the National Cancer Institute in 1937. Dr. Dudley Jackson refused.
• 1945 George Dick resigns suddenly as head of the department of medicine at Chicago Univerrsity and his successoris hostile to Revici and his methods.
• 1945: Stranded in the US, Revici permanently settles to New York City. Passes the examination for his New York State medical license on the first attempt.
• 1946 Revici interviews doctors to work with, chooses Abraham Ravich
• In March 1947, this group chartered two non-profit organizations; the Institute of Applied Biology (IAB), and the Cancer Research and Hospital Foundation. founds the second Institute of Applied Biology in Brooklyn, New York.Turn coat Gustave Freeman joins them.
• In April 1947, Gustave Freeman sent a detailed letter to an associate editor of the Journal of the American Medical Association, providing information on Revici and the nature of the Institute of Applied Biology’s clinical research. Most likely, Freeman was responding to an American Medical Association request for background on Revici, because his letter touched on the story about Revici testing his method in Chicago. Freeman told the editor that conditions and facilities didn’t permit Revici to treat any patients at the University of Chicago hospital.
  
  
• Then, on January 8, 1949, the Journal of the American Medical Association ran a report by the American Medical Association Council on Pharmacy and Chemistry, headed “Cancer and the Need for Facts.” The report named various individuals and groups as charlatans and purveyors of quackery, Revici and the Institute of Applied Biology among them. The sole basis for including Revici appeared to be the 1945  Journal of the American Medical Association’s  warning.
• Revici meets with Albert Einstein to help formulate a mathematical definition of lipids.
• Reads his paper on abnormal fatty acids (leukotrienes) produced by radiation at the Sixth International Congress of Radiology in London. Revici’s paper predates the findings of leukotrienes by Bengt Samuelsson who was awarded the Nobel Prize in 1982. Biochemist Barry Sears, Ph.D., bases much of his groundbreaking book, The Zone, on the work of Samuelsson. (Revici further discusses these “abnormal trienically-conjugated fatty acids” in his textbook published in 1961, and reprinted in 1997).
• 1952 Purchases Trafalgar Hospital in Manhattan. Revici becomes medical director and chief of oncology. Relocates the IAB to a site across the street.
• 1961 Revici publishes his major textbook, Research in Physiopathology As [A] Basis For Guided Chemotherapy. (D. Van Nostrand). The work details Revici’s researchbased paradigm shifts, including the theory of biological dualism, the theory of hierarchic organization, and Revici’s theory of evolution.
• After reviewing his book in depth, The Society for Promoting International Scientific Relations, whose board includes 14 Nobel Prize winners, awards Revici its annual medal.
• The Journal of the American Medical Association (JAMA) publishes what is later demonstrated to be a fictitious report about Revici’s methods. Among other things, the report discusses the ineffectiveness of 345 Appendix A Revici’s method while treating 52 “phantom” patients at the University of Chicago. A written FBI report confirms that Revici never treated any patients at the University of ChicagoThe CAG report appears in JAMA claiming Revici’s method has no effect. One so-called co-author physician calls the report “a disgrace.” Another co-author of the CAG report who was President of the Nassau County Medical Society, writes to the President of the United States in favor of Revici’s method, and has his wife’s cancer treated by Revici personally. The report is contradicted by 100 pages of documented evidence and the written eyewitness account of Robert Fishbein, M.D.
• In Rome Professor Bizru gives a lecture before the Congress of Radiology where he reports the excellent results he has achieved using the Revici method.
• Revici corresponds with Professor Joseph Maisin of Belgium, formerly president and editor of the International Union Against Cancer and renowned as an authority in cancer. Working with terminally-ill patients, Maisin utilizes many of Revici’s methods with startling 347 Appendix A results. The correspondence ends when Maisin is killed in a car accident in 1971.
• Revici treats 3,000 heroin and methadone addicts with two lipidic substances, physically detoxifying the great majority in 3 to 7 days with no withdrawal symptoms. House Select Committee on Crime holds a hearing on narcotic addiction. Daniel Casriel, M.D. gives testimony on the superior results achieved in the treatment of narcotic addiction with Dr. Revici’s compounds. A feature article in Barrons (9/11/72), reports on Revici’s amazing addiction treatments.
• Revici closes Trafalgar Hospital because of financial difficulty (the hospital had been chartered as a non-profit health facility).
• Then, in November 1983 and again in January 1984, the deadliest attacks ever mounted against him commenced in the federal court and before the Office of Professional Medical Conduct.¹⁷⁰ In the court, he faced two malpractice suits, the first major negligence actions against him in 63 years of continuous practice. After 63 years of devoted patient care, Revici is sued for the first time, by three patients with the same lawyer. Revici prevails in all three cases. One case, Schneider vs Revici, establishes a precedent-setting decision. The U.S. Court of Appeals sees “no reason why a patient should not be allowed to make an informed decision to go outside currently approved medical methods in search of an unconventional treatment.”
• Edoardo Pacelli, M.D. in Naples, Italy, reports his results with 372 terminal patients using the Revici Method. Compared to the results reported with standard chemotherapy, the results are nothing short of phenomenal.
• Revici pays a house call to a patient who is too sick to see him, climbing five flights of stairs. Revici is ninety-three.
• The Office of Technology Assessment, an investigative arm of Congress, issues a report on unconventional cancer treatments, including the Revici Method. Seymour Brenner, M.D., board-certified radiation oncologist, testifies as to the successful results he has seen Revici achieve with cancer patients.
• Revici moves his offices to mid-town Manhattan.
• In 1993, at age 96, Revici’s medical license is revoked due to inadequate record keeping.
• Revici celebrates his 100th birthday. Accolades come from doctors, researchers, friends, former patients, reporters, and government leaders including Governor Pataki (NY) and President Clinton.
• In Zimbabwe the James Mobb Clinic reports that protocols developed by Revici are superior to treatments using protease inhibitors, enabling wheelchaired AIDS patients back to work in weeks.
• At the F.A.I.M. (Foundation for the Advancement of Innovative Medicine) conference in New York, Revici receives an extended standing ovation for his lifetime of extraordinary achievement.¹⁷¹
• In 1996, at 100 years of age, Kelley Eidam writes Revici’s biography.
• January 9, 1998 Revici dies in his home in New York, after 77 years of practice and curing thousands upon thousands of people with so called uncurable diseases.
• His institute is run by Dr Korin during his illnss, thenby Dr. Joseph Carozzi.  and now by Dr Revici’s grandson.
• The Revici Life Science Center Inc.
  200 West 57th St, Suite 402,
  New York, NY 10019.
  Tel: 212 252-1942¹⁷²

Commentary and Conclusion

Revici was a hero in his home country Romania, and also France and Mexico. He was then lured to the US under false pretenses, and treated horribly culminating in his license being revoked, even though he cured thousands upon thusands of supposedly incurable diseases, and other doctors stealing his ideas and passing them off as their own.

It’s a heart breaking story of a doctor who only wanted to help people being vilified and sabotaged by evil people.

The real attacks on his person coincide with sadistic, racist chemical warfare specialist Rhoades becoming director of Sloan ketteing. Look at the trap they ste up for Revici. Luring him to the US, arranging for the letter signed by the 50 physicians. It’s almost funny if it weren’t so disgusting how these criminals are so used to doing crime they make sleepy bureaucratic mistakes, like forgetting to update to the fact that he never wentto Chicago. Or did George Dick resign by surprise after which they had to improvise? Was this conspiracy against Revici perhaps too much for george Dick, and was that why he resigned suddenly, and didother criminals not get the memo, and is that why they went ion with their false allegations that Revici treated 52 patients n Chicago without effect?

And then they had to think on their feet. Send Freeman to work with Revici and have him slander him. How pathetic.

What would have happened if Revici were less apolitical? What if he had just accepted all those honours presidents wanted to bestow on him, accepted the money. Rise above all those vilified him.

He should have gone back to France after the war. He should never have gone to theUS. The warning signs were already there.

If an angel would come to earth you would expect him to be like Revici. Maybe he was one.

And his license was revoked. I can’t find most of his papers online, while a head of chemical warfare chemo therapy drugs based on mustard gas making racist and sadist Rhoads is honoured yearly at Sloan Kettering.

The Burrs, discovered Linoleic-Acid and Alpha Linolenic Acid were essential nutrients, Emanuel Revici discovered they were cancer cures, as well as cures for many other diseases, and he explained why.

Johanna Budwig cured cancer even faster than Emmanuel Revici did. We’ll discuss her next.

Footnotes

1Dr. Emanuel Revici MD. Explains his cancer treatment, Repeater, September 12, 2019,

https://youtu.be/TE8P2aOBfDw?t=1074

2 Revici E, 1961, op cit.; Also: Simopoulos AP, Robinson J. The Omega Plan. New York, NY: Harper Collins, 1998:61-74. Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

3https://www.townsendletter.com/AugSept2006/revici30806.htm

4Dr. Emanuel Revici MD. Explains his cancer treatment, Repeater, September 12, 2019, https://youtu.be/TE8P2aOBfDw?t=1528

5https://scentses4d.wordpress.com/2021/09/26/the-20-essential-minerals/

6Dr. Emanuel Revici MD. Explains his cancer treatment, Repeater, September 12, 2019, https://youtu.be/TE8P2aOBfDw?t=3264

7Lesion: A lesionis any damage or abnormal change in the tissue of an organism, usually caused by diseaseor trauma. Lesionis derived from the Latin laesio“injury” .Wikipedia,last edited on 14 January 2022 https://en.wikipedia.org/wiki/Lesion#:~:text

8Dr. Emanuel Revici MD. Explains his cancer treatment, Repeater, September 12, 2019, https://youtu.be/TE8P2aOBfDw?t=3264

9Revici’s research has demonstrated that lipids have an affinity for tumors and other abnormal tissues. Because of this, the lipids or lipid-like synthetic compounds administered to the patient, either by mouth or injection, travel directly to the tumor or lesion. Cancerous tissue is abnormally rich in free lipids, and the lipidic agents introduced into the bloodstream are readily taken up by the tumor. Cancer: Revici Therapy by Richard Walters http://rexresearch.com/reviciselenium/revici.html http://www.healthy.net/Health/Article/Revici_Therapy/2013/3

10Beta-carotene and Vitamin A. Scentses4d, February 16, 2021, Anna Elize,

https://scentses4d.wordpress.com/2021/02/16/beta-carotene-and-vitamin-a/

11Vitamin D, Calcium, Magnesium, Vitamin K2, Vitamin B5, Co enzyme A, Cholesterol and Sunlight, May 29, 2019, Anna Elize, https://scentses4d.wordpress.com/2019/05/29/vitamin-d-calcium-magnesium-and-vitamin-k/

12Vitamin E, Scentses4d, November 12, 2020, Anna Elize, https://scentses4d.wordpress.com/2020/11/12/vitamin-e/

13B Vitamins, Scentses, February 18, 2021, Anna Elize,

https://scentses4d.wordpress.com/2021/02/18/b-vitamins/

14Dr. Emanuel Revici MD. Explains his cancer treatment, Repeater, September 12, 2019,

, https://youtu.be/TE8P2aOBfDw?t=4378

15Dr. Emanuel Revici MD. Explains his cancer treatment, Repeater, September 12, 2019, https://youtu.be/TE8P2aOBfDw?t=1700

16Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961,Revici, Emanuel, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

17Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

18Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

19Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

20EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

21Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

22https://en.wikipedia.org/wiki/Bengt_I._Samuelsson

23Samuelsson, 1987

24Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

25Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

26Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

27Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

28Mizushima, et al, 1986 https://scholar.google.fr/scholar?q=Mizushima,+et+al,+1986&hl=en&as_sdt=0&as_vis=1&oi=scholart Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come, PMC, July 2016, Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev. 2016 Jul;68(3):701-87. doi: 10.1124/pr.115.012070 PMID: 27363439 ; PMCID: PMC4931871.Phatsapong Yingchoncharoen, Danuta S. Kalinowski, and Des R. Richardson , Molecular Pharmacology and Pathology Program, Department of Pathology, Faculty of Medicine, Bosch Institute, The University of Sydney, Sydney, NSW, Australia

Corresponding author.

Address correspondence to: Dr. Des R. Richardson, Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, The University of Sydney, Blackburn Building D06, Sydney, NSW 2006, Australia., E-mail: ua.ude.dysu.dem@nosdrahcir.d

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931871/

29Revici Journal, Written by Lynne August MD , who spent five years under the tutelage of Emanuel Revici MD https://www.drrevici.com/

30Revici Journal, Written by Lynne August MD , who spent five years under the tutelage of Emanuel Revici MD https://www.drrevici.com/, https://theconversation.com/how-does-your-body-burn-fat-97813 , https://www.drrevici.com/lynne-august-md Her business is Called “Health Equations” https://www.healthequations.com/about

31Vegetable oils: which are healthy, and how should they be consumed?Scentses4d, March 14, 2021, Anna Elize,

https://scentses4d.wordpress.com/2021/03/14/vegetable-oils-which-are-healthy-and-how-should-they-be-consumed/

32The 21 amino acids and their food sources, Scentses4d, September 26, 2021, Anna Elize,

https://scentses4d.wordpress.com/2021/09/26/the-21-amino-acids-and-their-food-sources/

33https://www.nature.com/scitable/topicpage/dynamic-adaptation-of-nutrient-utilization-in-humans-14232807/

34 Vegetable oils: which are healthy, and how should they be consumed?Scentses4d, March 14, 2021, Anna Elize,

https://scentses4d.wordpress.com/2021/03/14/vegetable-oils-which-are-healthy-and-how-should-they-be-consumed/

35Selenium, Scentses4d, September 8, 2021, Anna Elize, https://scentses4d.wordpress.com/2021/09/08/selenium/

365. Prof. Mark D. Noble originally prepared the section here on Revici’s scientific findings and medical applications for an appraisal of Revici published in The Journal of Alternative and Complementary Medicine. 1998; 4 (2).

37Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

38Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

39Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

40https://chem.libretexts.org/Bookshelves/General_Chemistry/Book%3A_Structure_and_Reactivity_in_Organic_Biological_and_Inorganic_Chemistry_(Schaller)/I%3A__Chemical_Structure_and_Properties/08%3A_Introduction_to_Biomolecules/8.01%3A_Lipids

41Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

42Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

43Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

44Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

45Leukotrienes and lipoxins: structures, biosynthesis, and biological effects, Science, September 4, 1987, Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987 Sep 4;237(4819):1171-6. doi: 10.1126/science.2820055, PMID: 2820055.Samuelsson B, Leukotrienes. Science. 1987;237:1171-1176. B Samuelsson, S E Dahlén, J A Lindgren, C A Rouzer, C N Serhan https://pubmed.ncbi.nlm.nih.gov/2820055/

46Leukotrienes and lipoxins: structures, biosynthesis, and biological effects, Science, September 4, 1987, Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987 Sep 4;237(4819):1171-6. doi: 10.1126/science.2820055, PMID: 2820055.Samuelsson B, Leukotrienes. Science. 1987;237:1171-1176. B Samuelsson, S E Dahlén, J A Lindgren, C A Rouzer, C N Serhan https://pubmed.ncbi.nlm.nih.gov/2820055/

47Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

48Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

49Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

50Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici20806.htm

51The Nobel Prize in Physiology or Medicine 1982 was awarded jointly to Sune K. Bergström, Bengt I. Samuelsson and John R. Vane

“for their discoveries concerning prostaglandins and related biologicallyactivesubstances.https://www.nobelprize.org/prizes/medicine/1982/summary/

52Dr. Emanuel Revici, MD, Dr. Revici.com,Lynne August MDhttps://www.drrevici.com/emanuel-revici-md

53Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

54The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem. https://www.amazon.com/Doctor-Who-Cures-Cancer-ebook/dp/B0063916KK

55Dr. Emanuel Revici MD. Explains his cancer treatment, Repeater, September 12, 2019,

, https://youtu.be/TE8P2aOBfDw?t=1700

56EVALUATION OF RESULTS USING THE REVICI METHOD, Seymour Brenner, M.D., F.A.C.R., http://www.iraheller.com/Revici/Results.htm

57The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem. https://www.amazon.com/Doctor-Who-Cures-Cancer-ebook/dp/B0063916KK

58The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem. https://www.amazon.com/Doctor-Who-Cures-Cancer-ebook/dp/B0063916KK

59EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

60Joseph Maisin, Obituary, https://www.jstor.org/stable/3573281

61(personal communications to Revici ; 2/26/65, 3/8/67, 3/18/68,11/11/69,1/13/70; Office of Technology Assessment, 1990). EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

62 (personal communication to the Board of Regents of the University of the State of N.Y., 2/14/86, in an administrative proceeding that is a matter of public record). EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

63 (personal communication to the N.Y. State Department of Education, 1/20/97, entered into the record of Revici’s re-licensing proceeding).EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

64The importance of the ratio of omega-6/omega-3 essential fatty acids. PubMed, September 11, 2002, 2002 Oct;56(8):365-79. doi: 10.1016/s0753-3322(02)00253-6. PMID: 12442909.Biomed Pharmacother. https://pubmed.ncbi.nlm.nih.gov/12442909/ Received 25 May 2002, Accepted 6 June 2002, Available online 11 September 2002, A P Simopoulos.The Center for Genetics, Nutrition and Health, Washington, DC 20009, USA. cgnh@bellatlantic.net https://www.sciencedirect.com/science/article/abs/pii/S0753332202002536?via%3Dihub

65The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem. ^{https://www.amazon.com/Doctor-Who-Cures-Cancer-ebook/dp/B0063916KK}

66Dr. Emmanuel Revici, The Einstein of Medicine, First Step, Cuteman, https://codepen.io/cuteman100/full/oYqRPa

67The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem., https://www.amazon.com/Doctor-Who-Cures-Cancer/dp/1438263902

68The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem.,(p. 5). CreateSpace. Kindle Edition.https://www.amazon.com/Doctor-Who-Cures-Cancer/dp/1438263902

69The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem., (pp. 6-8). CreateSpace. Kindle Edition. The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem. ^{https://www.amazon.com/Doctor-Who-Cures-Cancer- ebook/dp/B0063916KK} , https://www.amazon.com/Doctor-Who-Cures-Cancer/dp/1438263902

70affidavit, Revici, 1955, p. 2 https://www.amazon.com/Doctor-Who-Cures-Cancer/dp/1438263902 The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem. ^{https://www.amazon.com/Doctor-Who-Cures-Cancer- ebook/dp/B0063916KK} , https://www.amazon.com/Doctor-Who-Cures-Cancer/dp/1438263902

71C. Pouret, archivist, National Academy of Sciences (France), letter to Dr. Revici, 5/1/85.

Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, ^{https://www.townsendletter.com/AugSept2006/revici30806.htm}

72Eidem, William Kelley. The Doctor Who Cures Cancer (pp. 8-9). CreateSpace. Kindle Edition. https://www.amazon.com/Doctor-Who-Cures-Cancer/dp/1438263902

73The Doctor Who Cures Cancer CreateSpace. 2009. William Kelley Eidem., (p. 9). .https://www.amazon.com/Doctor-Who-Cures-Cancer/dp/1438263902

74Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://go.gale.com/ps/i.do?id=GALE%7CA122581686&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15254283&p=AONE&sw=w&userGroupName=anon%7E84acdcf4

75Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm#1936

76Dr. Emanuel Revici, INTERNATIONAL FOUNDATION FOR NUTRITION AND HEALTH

Keeping The Spirit Of The Lee Foundation Alive, https://ifnh.org/dr-emanuel-revici/

77Personal communication from Andre Girard, a leader of the French Resistance in southern France, to Laurence H. Eldredge, Esq., 4/12/65; also, affidavit, Revici, 1955, p. 3Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

78Emanuel Revici. Affidavit; sworn and notarized, 2/3/55. Extending 41 pp., this document detailed Revici’s life and career from 1896 to 1955. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

79Emanuel Revici. Affidavit; sworn and notarized, 2/3/55. Extending 41 pp., this document detailed Revici’s life and career from 1896 to 1955. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

80Affidavit, Revici, 1955, pp. 4-22. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

81https://scentses4d.wordpress.com/2021/09/26/the-20-essential-minerals/

82Emanuel Revici. Affidavit; sworn and notarized, 2/3/55. Extending 41 pp., this document detailed Revici’s life and career from 1896 to 1955. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

83Affidavit, Revici, 1955, pp. 23-26. and http://www.healthwakeup.co.za/pdfdocuments/TownsendLetter.pdf Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

84George Frederick Dick, https://en.wikipedia.org/wiki/George_Frederick_Dick#/media/File:George_Frederick_Dick.jpg

85George Frederick Dick, wikipedia, July 12, 2021,  https://en.wikipedia.org/wiki/George_Frederick_Dick

86(personal communication, A. Girard to L.H. Eldredge, 4/12/65) EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

87Sumner Welles, American diplomat, Library of Congress‘s Prints and Photographs division under the digital ID cph.3b12340. https://en.wikipedia.org/wiki/Sumner_Welles#/media/File:Sumner_Welles_cph.3b12340.jpg

88http://www.healthwakeup.co.za/pdfdocuments/TownsendLetter.pdf page 3Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

89http://www.healthwakeup.co.za/pdfdocuments/TownsendLetter.pdf Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

90The Revici Life Science Center Inc.
200 West 57th St, Suite 402,
New York, NY 10019.
Tel: 212 252-1942

The Cancer Cure Foundation, https://www.cancure.org/10-list-of-clinics-in-the-united-states-offering-alternative-therapies/98-emanuel-revici

91Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm#1936

92Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, 1961,

https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

93 Affidavit, Revici, 1955, pp. 38-40, and personal communication from Benjamin C. Ribman, Esq., to the American Medical Association, 1/28/49.Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

94Revici et al, 1953, Anti-Hemorrhagic Action of n-Butanol in Advanced Cancer, PubMed, December 4, 1953, REVICI E, RAVICH RA. Anti-hemorrhagic action of n-butanol in advanced cancer. Angiology. 1953 Dec;4(6):510-5. doi: 10.1177/000331975300400606

. PMID: 13105026. https://pubmed.ncbi.nlm.nih.gov/13105026/ Revici et al, 1954, Willheim et al, 1959 https://scholar.google.fr/scholar?hl=en&as_sdt=0%2C5&as_vis=1&q=Revici+et+al%2C&btnG= https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/canjclin.39.2.119 Unproven Methodsof Cancer Management:

Revici Method, CA-A CANCERJOURNALFORCLINICIANS https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.3322/canjclin.39.2.119

95Revici, paper titled “The Influence of Irradiation upon Unsaturated Fatty Acids,” read before the Sixth International Congress of Radiology, London, 1950; Kaempffert, 1951; Schmeck, 1959; Revici, address before the Society for Promoting International Scientific Relations, 1961.EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

96Leake et al, 1945, Council on Pharmacy and Chemistry, 1949.EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

97Institute of Applied Biology, 1949EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

98retraction, authorized and signed by the Brooklyn Cancer Society, 6/13/49EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

99Laurence, 1952EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

100Personal communication from Edward M. Crane, president of Van Nostrand, to the Institute of Applied Biology, 6/8/61EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

101Revici, 1961, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961,Emanuel Revici, https://hdl.handle.net/2027/mdp.39015003770982 , ^{https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3} and ^{https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html}

102American Cancer Society, 1961.EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

103American Cancer Society, 1989EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

104Personal communication from B.C. Ribman, Esq., to the A.M.A., 1/28/49; F.B.I. dossier on Revici, 1959.

105American Cancer Society, 1989.EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

106Unpublished memorandum by the Committee on Cancer Diagnosis and Therapy, National Research Council, 2/17/53; unpublished commentary by Abraham Ravich, MD, Institute of Applied Biology, to Dr. George Lull, executive director, American Medical Association, 7/14/53.EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

107Paper, titled “Cancer: Concept, Method, Therapy of Emanuel Revici, MD,” stating in the addenda that it “was the topic of discussion” at meetings with the N.C.I., 6/5-6/62.EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

108Lyall et a], 1965; personal communication, A. Girard to L.H. Eldredge, 4/12/65EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

109 Office of Technology Assessment, 1990.EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

110American Cancer Society 1989 EMANUEL REVICI, M.D., INNOVATOR

IN NONTOXIC CANCER CHEMOTHERAPY, Marcus A. Cohen http://www.iraheller.com/Revici/About_Dr_Revici.htm

111 Identification of two of the three doctors added to the committee Angrist chaired at Queens General is not certain. Bodansky is almost certainly Oscar Bodansky; Gellhorn is probably Alfred Gellhorn. Later, Bodansky and Gellhorn were affiliated with more prestigious institutions. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://go.gale.com/ps/i.do?id=GALE%7CA122581686&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15254283&p=AONE&sw=w&userGroupName=anon%7E84acdcf4

112Laurence W. Cancer attacked by a new method. The New York Times. 12/2/52. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://go.gale.com/ps/i.do?id=GALE%7CA122581686&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15254283&p=AONE&sw=w&userGroupName=anon%7E84acdcf4

113Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici20806.htm

114 Revici E and Ravich A. Anti-hemorrhagic action of n-butanol in advanced cancer. Angiology. 1953;4:510–515. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://go.gale.com/ps/i.do?id=GALE%7CA122581686&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15254283&p=AONE&sw=w&userGroupName=anon%7E84acdcf4

115Kaempffert W. Burns are treated with n-butanol. “Science In Review”. The New York Times. 3/4/51.

116Letter from Robert Ravich, MD, to Mrs. Ethel Pratt, 11/12/55.

117The following list represents a selection of papers published in the peer review literature by Revici and his colleagues at the IAB. The full list, seven pages long, was compiled by the late Prof. Harold Ladas, a patient of Revici. With his wife, Dr. Alice Ladas, Harold Ladas organized and helped fund Revici’s patients in their successful campaign to prevent the NY Health Dept. (OPMC) from revoking Revici’s medical license in the mid-1980s. An asterisk at the beginning of a citation signals that Revici was a co-author.

• *Blechmann M, et al. The effect of unsaponifiable fraction of lipids (sterols) on morphology and growth metabolism of mycobacterium tuberculosis var. hominis and var. bovis (BCG). The American Review of Respiratory Diseases. 1964;89(3): 448–49.
• *Blechmann M, et al. Ring and lysis zones in cultures of tubercle bacilli in medium enriched with unsaponifiable lipid fractions The American Review of Respiratory Diseases. 1963;87(5).
• LeShan L. Psychological states as factors in the development of malignant
  disease: a critical review. J Nat. Cancer Inst. 1959; 22 : 1–18.
• LeShan L. Basic psychological orientation apparently associated with malignant
  disease. Psychiatric Quarterly. 1961.
• LeShan L. The world of the patient in severe pain of long duration. J. Chronic
  Diseases. 1964; 17: 119–26.
• Ravich RA. Relationship of colloids to the surface tension of urine. Science.
  1953;117: 561.
• Ravich RA. Pain—controlled and uncontrolled. Science. 1953;118 (3057): 144–45.
• Revici E, et al. Surface tension of urine in old age. Geriatrics. 1954;9(8) : 386–89.
• Welt B. Head and neck pain: role of biological imbalance in its pathogenesis and
  therapy. AMA Archives of Otolaryngology. 1955; 61:280–312.
• Welt B. Vertigo: a further contribution to therapy based upon its
  physiopathological aspect. Archives of Otolaryngology. 1956; 63: 25–29.
• A letter from Henry L. Williams, MD, to Bernard Welt, MD, 1/29/54, referred to an article Prof. Ladas did not include in Institute of Applied Biology bibliography. Williams was at the Mayo Clinic, Rochester, Minnesota, Welt at the IAB. The full text of this short letter follows: “I read with considerable interest your article on a new theoretical approach in vertigo which came out in the September Archives [Archives of Otolaryngology, an American Medical Association journal]. I have tried your method of therapy on some cases of vertigo and several with headaches. They have given very good response.
  “I have been asked by the Academy of Ophthalmology and Otolaryngology to organize a symposium on the treatment of headache to be given in New York City for a two day period between September nineteenth and twenty- fourth. This is to be in the teaching section, a two hour session being held on each of the two days. The members of the panel will discuss their treatment for ten minutes apiece during the first hour. The second hour will be devoted to the answering of questions from any auditor present. Your therapy is extremely new and unusual and I would be very happy indeed if you would agree to be a member of this panel.”

118Schmeck HM, Jr. Chemists study adrenal action. The New York Times. 9/19/59. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://go.gale.com/ps/i.do?id=GALE%7CA122581686&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15254283&p=AONE&sw=w&userGroupName=anon%7E84acdcf4

119Letter from Fanny Holtzmann, esq., to S.A. Logan, First National City Bank, 4/13/55. The pertinent paragraph reads: “In the current issue of CANCER, official organ of the American Cancer Society (March, April 1955) there is an article by Dr. Marion Barclay, et al., entitled “Lip-Proteins in Normal Women and in Women with Advanced Carcinoma of the Breast.” The title carries the unusual footnote “The authors wish to thank Dr. Cornelius P. Rhoads for suggesting this problem and for his continuing support and interest.” The article concludes that cancer patients have abnormal Lip-Protein metabolism “which is associated with a severe defect in lipid metabolism. This is precisely the premise from which Dr. Revici set out on his biochemical explorations more than thirty years ago”. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://go.gale.com/ps/i.do?id=GALE%7CA122581686&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=15254283&p=AONE&sw=w&userGroupName=anon%7E84acdcf4

120Letter from Edward M. Crane to Mrs. Sherman Pratt. 6/8/61 Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici20806.htm

121Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici20806.htm

122Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 2, Townsend letter, The Examiner of Alternative Medicine, October 2004, Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici20806.htm

123Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 1, Townsend letter, The Examiner of Alternative Medicine, August/September 2004, by Marcus A. Cohen, https://www.townsendletter.com/AugSept2006/revici10806.htm

124Charles Oberling, wikipedia, Updated January 13, 2022, https://fr.wikipedia.org/wiki/Charles_Oberling and Charles Oberling, Research Worker on the Nature of Cancer, CE Science, November 25, 1960, Peyton Rous, 25 Nov 1960 • Vol 132, Issue 3439 • pp. 1534-1535 • DOI: 10.1126/science.132.3439.1534, PEYTON ROUS https://www.science.org/doi/10.1126/science.132.3439.1534

125Charles Oberling, wikipedia, Updated January 13, 2022, https://fr.wikipedia.org/wiki/Charles_Oberling

126The graduation Gown of Professor Charles Oberling on its way to Iran, April 22, 2017, Tehran Universityof Medical Studies (TUMS), Reported By: Sahar Mohammadian

Edited By: M. Davoodifar, https://gsia.tums.ac.ir/IHESeminar/ndt/352508/The-Graduation-Gown-Toga-of-Professor-Charles-Ober

127Charles Oberling, wikipedia, Updated January 13, 2022, https://fr.wikipedia.org/wiki/Charles_Oberling Charles Oberling, wikipedia, Updated January 13, 2022, https://fr.wikipedia.org/wiki/Charles_Oberling

128Charles Oberling, Wikipedia, Updated January 13, 2022, https://fr.wikipedia.org/wiki/Charles_Oberling

129Office of Strategic Services, Wikipedia, edited March 20 , 2022,

https://en.wikipedia.org/wiki/Office_of_Strategic_Services

1. 130Cornelius P. Rhoads in Army uniform NIH – Images from the History of Medicine – probably U.S. Army – Original publication: 1943 http://ihm.nlm.nih.gov/luna/servlet/detail/NLMNLM~1~1~101427234~187669:-Cornelius-P–Rhoads-  Cornelius P. Rhoads in Army uniform, wikipedia, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads#/media/File:Cornelius_P._Rhoads_Army_portrait.jpg

131Truman R. Clark. 1975. Puerto Rico and the United States, 1917-1933, University of Pittsburgh Press, pp. 151-154 https://books.google.fr/books?id=tDZtGZoFSGYC&pg=PA141&redir_esc=y#v=onepage&q&f=false Cornelius P. Rhoads, Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads

1. 132 Susan E. Lederer, “Porto Ricochet”: Joking about Germs, Cancer, and Race Extermination in the 1930s”, American Literary History, Volume 14, Number 4, Winter 2002, pp. 720–746 https://muse.jhu.edu/article/1989

Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads

133https://en.wikipedia.org/wiki/Mustard_gas

134Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads

135https://www.ncbi.nlm.nih.gov/books/NBK548509/

136Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads

137Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads

138Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads

139Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads Cornelius P. Rhoads,Wikipedia, edited March 31, 2022, https://en.wikipedia.org/wiki/Cornelius_P._Rhoads

140Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm#1936

141Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm#1936

142Revici, Emanuel, Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, 1961,

https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

143Jackson, Dudley, Sr. (1890–1959), Texas State Historical Association (TSHA),Published: February 1, 1995

Updated: April 25, 2019, Patricia L. Jakobi, https://www.tshaonline.org/handbook/entries/jackson-dudley-sr

144Chauncey D. Leake,Wikipedia, edited january 10, 2022, https://en.wikipedia.org/wiki/Chauncey_D._Leake

145Drs. Leake and Fishbein at consultants meeting, National Library of Medicine, 1960, Images from the Hiuistory of medicin, https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101445697-img https://en.wikipedia.org/wiki/Chauncey_D._Leake#/media/File:Chauncey_Leake_and_Morris_Fishbein.jpg

146Abraham Ravich, Prabook, https://prabook.com/web/abraham.ravich/790435

147Abraham Ravich, Prabook, https://prabook.com/web/abraham.ravich/790435

148Abraham Ravich, MD. Letter to André Girard. 4/5/47 , Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm#1936

149Gustave Freeman, Find a Grave,https://nl.findagrave.com/memorial/141251355/gustave-freeman

150https://www.tandfonline.com/doi/abs/10.1080/089583798197484

151Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm#1936

152Ravich A, MD. Institute of Applied Biology. Correspondence. JAMA. 1949;140:908 from Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm#1936

153https://www.townsendletter.com/AugSept2006/revici30806.htm#1936 manuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

154https://www.oncolink.org/cancer-treatment/complementary-and-alternative-medicine/therapies/the-revici-method-for-the-treatment-of-cancer

155House Select Subcommittee on Crime, U.S. Congress, 1971, Barron’s, 1972, Toxicomanies, 1973, Revici v. N.Y. News Incorporated and William Sherman, 1977.manuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

156 N.Y. State health department manuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

157Schneider v. Revici, 1985, 1987, and Boyle v. Revici, 1989, 1992manuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

158 Boyle v. Revici, 1994.manuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

159Schneider v. Revici, 1987.manuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

160U.S. Congress, notably The Access To Medical Treatment Act, pending before both Houses since 1994, and notably the report delivered to President George Bush by the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS, 1990.manuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

161Wennberg, 1988,1990, and Reiser, 1993.manuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

162Revici, 1961 Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, 1961,

https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html

163Revici, 1961Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, 1961,

https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html ; Schrauzer, 1981.

164 Revici, 1961Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, 1961,

https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html ; Simopoulos, et al, 1998

165212 252-1942 http://www.pieronuciari.it/wp/wp-content/uploads/2021/03/Thousand-Plants-against-Cancer-without-Chemo-20101.pdf

166Personal communication with Dr. Emanuel Revici, c. 1984

167Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961,Emanuel Revici, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/Bibliography-Part-4.html

168Research in physiopathology as basis of guided chemotherapy, D. van Nostrand Company, Inc, November 13, 1961,Emanuel Revici, https://hdl.handle.net/2027/mdp.39015003770982 , https://babel.hathitrust.org/cgi/pt?id=mdp.39015003770982&view=1up&seq=3 and https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/index.html https://chestofbooks.com/health/disease/cancer/Emanuel-Revici-Research-Physiopathology/Bibliography-Part-4.html

169Emanuel Revici. Affidavit; sworn and notarized, 2/3/55. Extending 41 pp., this document detailed Revici’s life and career from 1896 to 1955. Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, https://www.townsendletter.com/AugSept2006/revici30806.htm

170 N.Y. State health department Emanuel Revici, MD: Efforts to Publish the Clinical Findings of a Pioneer in Lipid-Based Cancer Therapy Part 3, Townsend letter, The Examiner of Alternative Medicine, August-September 2006, ,Marcus Cohen, ^{https://www.townsendletter.com/AugSept2006/revici30806.htm}

171Dr. Emmanuel Revici, The Einstein of Medicine, First Step, Cuteman, https://codepen.io/cuteman100/full/oYqRPa

172The Cancer Cure Foundation, https://www.cancure.org/10-list-of-clinics-in-the-united-states-offering-alternative-therapies/98-emanuel-revici

Back to top

Dandhea Book 1

Back to Index